Study_ID
string | Objectives
string | Included
string | Excluded
string |
|---|---|---|---|
CRD42024607528 | Evaluating the Efficacy of Isokinetic Muscle Strengthening Training in Improving Knee Osteoarthritis Outcomes. | Knee osteoarthritis (KOA) is a prevalent degenerative joint disease that is categorized as “paralysis” in the context of traditional Chinese medicine (TCM). The primary pathological manifestations of KOA include articular cartilage degeneration, and osteophyte formation. These changes can lead to a spectrum of symptoms including joint pain, reduced mobility, and severe disability. Furthermore, KOA increases the risk of complications such as lower extremity deep vein thrombosis and cardiovascular events. The prevalence of this condition is notably higher among the middle-aged and older populations. Isokinetic muscle strengthening training (IMST), recognized as a safe and non-invasive therapeutic approach, is widely employed to rehabilitate muscles affected by KOA, with the aim of enhancing muscle strength. Despite the abundance of clinical studies exploring the efficacy of IMST in treating KOA, these studies had limited sample sizes and a fragmented focus on specific outcome measures.
Furthermore, the field lacks systematic and comprehensive evaluation studies. Given these gaps, we aimed to conduct a meta-analysis of the existing literature on IMST for KOA treatment, to provide a more robust evidence-based foundation for clinical rehabilitation practices. Concurrently, the IMST data from lowland areas provided substantial clinical support for its application in treating KOA in the Qinghai-Tibet Plateau. | null |
CRD420250646638 | What is the relationship between nitric oxide (NO) and vascular endothelial growth factor (VEGF) in the vascular remodeling of congenital diaphragmatic hernia (CDH) across clinical and experimental studies? | Congenital Diaphragmatic Hernia (CDH) is a malformation of the diaphragm characterized by total or partial agenesis of the muscle. Its pathogenesis is linked to nitric oxide (NO) and vascular endothelial growth factor (VEGF), the key molecules of interest in this review. Human and/or animal models (Sprague Dawley rats, rabbits, sheep) with Congenital Diaphragmatic Hernia, all sexes. 1) Healthy Animals: Age-matched, non-CDH animals (rats, rabbits, sheep) that have not undergone CDH induction.2) Healthy humans that were matched to CDH patients.3) Lung and blood samples from healthy controls will be used to directly compare with those from CDH-affected individuals within the same species. | will be excluded if they involve a population not specified in the inclusion criteria, including any animal species not explicitly mentioned, animals with comorbities, in vitro. 1) not involving the specified animal models or human CDH cases.2) inadequate measurement or reporting of NO and VEGF.3) Studies with significant methodological inconsistencies. |
CRD42020203953 | How does mindfulness-based stress reduction and mindfulness-based cognitive therapy as a therapeutic means affect prehypertension and hypertension in adults compared to usual care or other interventions? | Hypertension. Prehypertension. MBSR/MBCT in adults. | null |
CRD420250639795 | Can the potential therapeutic mechanism of benzoylaconine (BAC) serve as a basis for the future development and use of BAC as a drug? | It does not involve research on human diseases. Male Wistar Rat model of MI induced, heart failure model of C57BL/6 male mice, Male SD rats of Ischemia/reperfusion (IR) model, SD rats of OA model, Male SD rats of CIA model, Female Kunming mice of inflammatory ear model, Male Wistar rats of adjuvant-induced arthritis model Blank. | null |
CRD42023388177 | The aim of our study is to identify, present, and appraise CPGs for non-pharmacological conservative management of CRPS and to describe the best recommended practice in the management of CRPS. | Complex regional pain syndrome (CRPS), which is a “chronic primary pain” condition, is a rare debilitating neurological condition that typically develops after a trauma or nerve injury. As its name implies, CRPS is a complex of signs and symptoms that are difficult to manage, and are usually out of proportionate to the primary impairment. | null |
CRD420250599111 | P: Breast Cancer Animal ModelI: Nanobody-based immunotherapyC: No comparatorO: Cancer Progression, Tumor Marker, Tumor Volume.S: Experimental Study | Breast cancer. Tumor immunotherapy. All animal models used to study breast cancer, including xenograft, orthotopic, syngeneic, and genetically engineered models. All species (e.g., mice, rats), both sexes, and all breast cancer subtypes (e.g., HER2+, triple-negative) are eligible. Studies must involve nanobody-based immunotherapy interventions and report outcomes related to efficacy, safety, or pharmacokinetics. - Vehicle-treated, untreated, or placebo controls - Standard treatments for breast cancer such as chemotherapy, monoclonal antibodies (e.g., trastuzumab), or other immunotherapies (e.g., checkpoint inhibitors) - Sham-treated groups in preclinical in vivo models - Alternative therapeutic agents used in experimental or clinical settings | Studies using animals with unrelated co-morbidities or disease models not representative of breast cancer; studies not involving nanobody interventions; and ex vivo, in vitro, or in silico models without any in vivo animal experimentation. Studies will be excluded if: - They do not include a control or comparator group - The comparator is not clearly described or relevant to breast cancer treatment - The comparator involves non-immunotherapeutic or non-oncologic agents not aligned with the scope of this review - They are single-arm studies or purely descriptive studies without any comparative analysis. |
CRD42025640083 | What are the therapeutic response rates and failure patterns associated with palliative systemic treatments in patients with metastatic, recurrent, or unresectable head and neck cancers? | Palliative systemic treatment outcomes in metastatic, recurrent, and unresectable head and neck cancers. | null |
CRD42021253134 | Is there a difference in clinical outcomes among patients with sacroiliac joint dysfunction when treated with surgical intervention compared to conservative therapy? | Sacroiliac joint dysfunction occurs in patients where the point of articulation between the lower spine and pelvis has increased mobility. This increased mobility causes inflammation in the area and leads to the patient experiencing pain. | null |
CRD420250625997 | Alzheimer's Disease (AD) is a devastating progressive neurodegenerative disorder marked by progressive cognitive decline, memory loss, and functional impairment. With the global aging population, the prevalence of AD is increasing at an alarming rate, placing enormous strain on families, caregivers, and healthcare systems. Despite ongoing research advancements in neuroscience, the current pharmacological treatments for AD, such as acetylcholinesterase inhibitors and NMDA receptor antagonists, offer only modest symptomatic relief and are often associated with adverse side effects and limited long-term efficacy. | Alzheimer's Disease (AD) is a chronic, progressive neurodegenerative disorder that primarily affects older adults. It is characterized by the gradual decline of cognitive functions, including memory, reasoning, and language, ultimately interfering with the ability to perform daily activities. AD is pathologically marked by the accumulation of amyloid-beta plaques, neurofibrillary tangles, oxidative stress, synaptic dysfunction, and chronic neuroinflammation. These alterations lead to the deterioration of neuronal structure and function, resulting in significant cognitive and behavioral impairments. Alzheimer's Disease represents the most common form of dementia and poses a substantial public health challenge due to its increasing prevalence, high care burden, and limited therapeutic options. Current treatments provide only modest symptomatic relief, without altering disease progression. As such, there is a growing interest in identifying and evaluating novel therapeutic approaches—particularly those based on nutritional and functional food interventions—that could support neuroprotection and slow or prevent disease progression. This systematic review focuses on the potential of Fish Protein Hydrolysates (FPH), derived from enzymatically processed fish proteins, which are rich in bioactive peptides known to exhibit antioxidant, anti-inflammatory, and neuroprotective properties. Understanding the role of FPH in mitigating AD pathology may provide insight into their utility as complementary or alternative treatments for Alzheimer's Disease. • Animal models used for studying Alzheimer's Disease (e.g., transgenic mice such as 5XFAD, APP/PS1, and other genetically modified or chemically induced AD models). • All species (primarily rodent models), regardless of sex. • Studies evaluating the neuroprotective, antioxidant, anti-inflammatory, or cognitive effects of Fish Protein Hydrolysates (FPH). • Studies with well-defined control and treatment groups. • Studies reporting outcomes related to AD pathology such as amyloid-beta accumulation, oxidative stress, inflammation, synaptic dysfunction, or behavioral/cognitive performance. • Peer-reviewed publications available in English. • Vehicle-treated control groups (e.g., animals or cells treated with saline, buffer, or placebo substances matching FPH formulation without active peptides). • Non-treated (baseline) groups used to assess the progression of Alzheimer's Disease-like symptoms or neurodegeneration. • Groups treated with conventional Alzheimer's Disease therapeutics such as donepezil, galantamine, rivastigmine, or memantine, as used in comparative preclinical or clinical trials. • Positive control groups treated with known neuroprotective agents or standard-of-care drugs used for benchmarking FPH efficacy. • In vitro models with untreated cells or cells treated with control peptide fractions or enzymatic digests lacking bioactivity. | • Animal studies involving co-morbid conditions not relevant to Alzheimer's pathology (e.g., diabetes, cardiovascular disorders without neurodegenerative context). • Studies lacking control groups or baseline comparison. • In vitro, ex vivo, or in silico models. • Studies where the intervention is not FPH or is part of a multi-compound treatment without isolated analysis of FPH effects. • Non-peer-reviewed articles, conference abstracts, and reviews. • Studies lacking a clearly defined control or comparator group. • Control groups where multiple variables are altered, making it difficult to isolate the effects of FPH. • Comparators involving combined treatments where the impact of FPH cannot be separated from other components. • Studies using historical or retrospective control data without standardization. |
CRD42024557720 | - Is surgical lymphedema treatment effective?
- Do different surgical techniques yield significantly different results when assessing for limb volume reduction?
- Does the severity of lymphedema cases have an impact on the effectiveness of volume reduction?
- Do different surgical approaches yield different quality of life outcomes?
- Is surgical lymphedema treatment more effective in severe cases of lymphedema when assessing quality-of-life outcomes? | Lymphedema is a worldwide condition primarily affecting cancer survivors. Additionally, there is primary lymphedema, which can develop in childhood or adulthood due to underdeveloped lymphatic tissue. This condition causes limb swelling, leading to heaviness, pain, and restricted mobility. The initial treatment typically involves conservative measures such as compression garments and repeated decongestive therapy. However, these interventions can significantly impact patients' quality of life, and they often provide limited reduction in limb volume. Consequently, patients often seek alternative treatments to alleviate these burdens and improve their quality of life. Surgical options for lymphedema treatment have advanced significantly over recent decades, resulting in a growing body of literature on this subject. | null |
CRD42018100458 | 1. What is the pharmacodynamics basis of why and how 11β-HSD1 inhibitors may or should be beneficial in therapeutic areas of Alzheimer's disease and dementia, anxiety, PTSD, depression, schizophrenia and bipolar, metabolic syndrome, obesity and diabetes ?
2. What is the therapeutic potential and health outcomes of 11β-HSD1 inhibitor use? | We are interested in understanding the role of 11beta-HSD1 in the following disease areas :
•Cognitive dysfunction (including mild cognitive impairment and all forms of dementia)
• Psychiatric diagnosis (anxiety, post-traumatic stress disorder, depression, schizophrenia and bipolar)
• Metabolic syndrome
• Obesity
• Diabetes | null |
CRD42023460093 | "What is the overall efficacy and safety profile of the PulseRider® device in the treatment of intracranial aneurysms, and how does it compare to other available treatment options?" | Brain aneurysms are weakened areas in the blood vessel walls of the brain that can lead to the formation of a bulging or ballooning sac. These sacs can potentially rupture and cause serious medical issues, including hemorrhagic strokes.The risk of developing brain aneurysms is influenced by various factors, including family history, age (with higher risk in middle-aged individuals), gender (more common in women), hypertension, smoking, drug abuse (particularly cocaine), heavy alcohol consumption, a history of head trauma, and certain medical conditions like polycystic kidney disease and connective tissue disorders. While these factors can increase the risk, not everyone with these factors will develop an aneurysm, and some individuals may develop one without identifiable risk factors. If there are concerns about aneurysm risk, consulting with a healthcare professional for personalized assessment and guidance on prevention and monitoring is advisable.Detecting brain aneurysms at an early stage is crucial as it enables proactive measures to prevent rupture and reduce associated risks. Early identification allows for informed decisions on treatment, potentially saving lives and minimizing the impact of aneurysms on patients' well-being. | null |
CRD42024527853 | To evaluate the diagnostic accuracy of contrast-enhanced ultrasound (CEUS) guided liver tumor biopsy | The incidence of liver tumors is high, especially malignant tumors, including primary liver cancer and metastatic liver cancer. Early diagnosis is very important for the next step of treatment. The pathological results obtained by puncture biopsy is the gold standard for the diagnosis of liver tumors. Ultrasound-guided puncture biopsy is the most commonly used method, and its clinical application is more and more extensive, but two-dimensional ultrasound examination shows some liver lesions are not clear, especially some occult liver cancer, two-dimensional ultrasound is very difficult to display, gray-scale and color Doppler ultrasound is difficult to identify the active part of space-occupying lesions or observe the vascular state within the space-occupying lesions, resulting in unsatisfactory samples. Contrast-enhanced ultrasound (CEUS) through intravenous injection of contrast agent can clearly show the blood flow and the active part of the focus, so the CEUS-guided puncture biopsy can accurately puncture to the smaller focus, which can clearly distinguish the substantial part from the necrotic and liquefied part, and improve the success rate of puncture. Therefore, this study further systematically evaluates the diagnostic value of CEUS-guided liver tumor biopsy. | null |
CRD42023410432 | What are the modalities of care and outcomes thereof in hepatocellular carcinoma with pulmonary metastasis?
What is the relationship between the total hepatocellular carcinoma population and the number of patients that develop pulmonary metastasis? | The condition that will be studied is pulmonary metastasis in hepatocellular carcinoma. The global trend of its incidence will be quantified and the relationship to the total HCC population will be described. The management and their respective outcomes will be critically analysed on a global scale. | null |
CRD42023485537 | P-Patients with an active cellulitis/bacterial skin infection/erysipela
I- Omadacycline
C- Linezolid
O- Reduction of infection
T- Therapy, RCT
T- No time limit | The primary bacterium responsible for Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) is Staphylococcus aureus (S. aureus). Nevertheless, the current medications utilized for treatment carry potential risks of adverse reactions. Considering these risks, there is an urgent need to investigate new drugs for ABSSSI treatment. These innovative medications should strive to improve therapeutic efficacy while reducing the overall treatment burden on patients. Our study intends to compare the effectiveness of Omadacycline in relation to Linezolid. | null |
CRD42023397373 | 1. To explore the efficacy of various commonly used external intervention methods using meta-analysis techniques.
2. To identify the best intervention measure or combination of measures.
3.To provide evidence for a better treatment plan for tennis elbow based on the new therapeutic evidence. | Tennis elbow, also known as external humeral epicondylitis (EHE), The main clinical manifestations were radioactive pain in the elbow downward along the forearm extensor group. The pain was aggravated when fists were clenched, wrists were extended, and forearm was rotated, accompanied by symptoms such as limited activity, tenderness and weakness. The main clinical manifestations were radioactive pain in the elbow downward along the forearm extensor group, and it occurred in the age group of 25–64 years old. Non-timely treatment will gradually develop into intractable tennis elbow, which has greatly affected the patients' daily life and work, and seriously affected their quality of life. In clinic, conservative external therapy is mainly applied to tennis elbow, and conservative treatment has proved effective in about 90% of patients [1]. In addition, a large number of clinical evidences show that external therapies of traditional Chinese and Western medicine have good clinical effects. However, no study has been conducted to compare the excellent effects of several external therapies commonly used for the treatment of tennis elbow horizontally. In this study, the meta of seven commonly used external therapies were investigated and meta-analyzed to further provide evidence for the selection of clinical treatment options for tennis elbow. | null |
CRD42023389133 | Could the treatment of Panax ginseng attenuate alcohol-associated liver disease in rodent models in vivo? | alcohol-associated liver liver disease Mice and rat experimental models with alcohol-associated liver liver diseases (all species and all sexes). All timings, frequencies, and dosages of treatment are eligible for inclusion. Vehicle-treated control animals. | Studies without animal experiments
In vitro experiments Studies with undefined time, frequency, or the dose of treatment are excluded.
Insufficient data of the primary outcomes Studies that used natural products other than Panax ginseng |
CRD420251030935 | Review Objectives: | This review will include studies involving: Human participants of any age group (adults, elderly, or pediatric populations), both healthy volunteers and patients, where the aim is to evaluate drug response, efficacy, metabolism, or adverse reactions influenced by pharmacogenomics, gut microbiota, epigenetic mechanisms, or artificial intelligence-based tools. Animal studies will be included only if they provide direct translational relevance to human drug response, such as mechanistic insights into microbiota-drug interactions, epigenetic modifications, or preclinical pharmacogenomic models. There will be no restriction on sex, ethnicity, or geographic location of participants. This review will include studies that investigate one or more of the following interventions or exposures with respect to drug action (efficacy, metabolism, toxicity, or clinical outcomes): Gut Microbiota: Studies examining the composition, modulation (e.g., probiotics, antibiotics, fecal transplants), or microbial metabolites affecting drug pharmacokinetics or pharmacodynamics. Pharmacogenomics (PGx): Research evaluating the influence of genetic polymorphisms (e.g., CYP450, TPMT, SLCO1B1) on drug metabolism, efficacy, or adverse reactions. Inclusion of clinically actionable gene-drug pairs supported by guidelines (e.g., CPIC, PharmGKB). Epigenetics: Studies investigating epigenetic changes such as DNA methylation, histone modifications, or microRNAs that alter drug response or resistance. Artificial Intelligence (AI): Use of AI, machine learning, or deep learning models for predicting drug efficacy, toxicity, or individual treatment outcomes using clinical or omics data. Tools integrating multi-omics or personalized profiles for drug selection or dosing. Note: Eligible studies may involve single or multi-domain exposures, provided they assess measurable drug response outcomes and contribute to understanding personalized pharmacology. PICO tags selected: Sham Intervention ; Gut microbial biomarker; Placebo This review will include studies that compare the impact of various biological or computational factors on drug response using one or more of the following comparators: Standard treatment or clinical care protocols, used as a reference to evaluate AI-based prediction tools or pharmacogenomic interventions. Wild-type versus mutant genotypes in pharmacogenomic studies, to assess differential drug efficacy or adverse effects. Different gut microbiota profiles, such as high vs low diversity or presence vs absence of specific microbial taxa, influencing pharmacokinetics or clinical response. Unmodified vs epigenetically altered models, in studies investigating DNA methylation or histone changes affecting drug metabolism or resistance. Non-AI vs AI-assisted decision-making, to evaluate improvement in precision medicine outcomes or prediction accuracy. Studies without an explicit control or comparator group will also be included if they provide mechanistic or translational insights into drug response | Studies involving only in vitro experiments, cell lines, or computational models without biological validation will be excluded. Animal studies that lack direct translational relevance to human health or drug response will be excluded. Studies involving non-therapeutic substances, such as dietary supplements without pharmacological intent, will be excluded. Populations with no reported drug exposure or drug response outcomes (e.g., purely diagnostic or screening studies) will be excluded. Conference abstracts, editorials, letters, or narrative opinions without original data or systematic review methodology will also be excluded. Studies that do not assess any direct impact on drug efficacy, metabolism, toxicity, or treatment outcomes will be excluded. Studies focusing solely on nutritional interventions (e.g., diet alone without pharmacological relevance) or microbiome diversity unrelated to drug action will be excluded. Pharmacogenomic studies that lack clinical correlation or only describe genetic variation frequencies without linking to drug response will be excluded. Epigenetic research without relevance to drug interaction or therapeutic modulation will not be included. Studies using AI exclusively for diagnosis, image analysis, or non-therapeutic prediction (e.g., disease risk without drug linkage) will be excluded. In vitro models, review articles without systematic methodology, and theoretical frameworks without experimental or clinical data will be excluded. Studies that use non-relevant comparators unrelated to drug action (e.g., comparisons between diagnostic modalities, imaging tools, or disease severity without assessing drug response) will be excluded. Comparisons that do not involve pharmacogenomic, microbiota, epigenetic, or AI-related factors in the context of drug therapy will be excluded. Studies comparing different nutritional regimens or lifestyle interventions without pharmacological endpoints will be excluded. Comparators involving non-human models without clear translational linkage to human pharmacological outcomes will not be considered. Articles that do not define or clearly describe the comparator group (e.g., unclear reference population or poorly reported control) will also be excluded. |
CRD420250653394 | 1: How good is adherence to CPAP therapy in randomised controlled intervention studies for obstructive sleep apnoea (OSA) in hours of use/night and percentage of patients using CPAP at least 4 h/night? 2: Are there predictors (patient or study design related) for inadequate (<4h) or good adherence to CPAP therapy in RCTs? | Continuous Positive Airway Pressure Ventilation ; Patient compliance; Obstructive Sleep Apnea Syndrome OSA is the disease of interest and CPAP adherance and its predictors the outcome of interest.Studies show that CPAP adherence in OSA patients is often suboptimal, with long-term adherence rates generally between 30 and 60 %. Although many patients initially use CPAP regularly, a significant proportion of them discontinue or reduce their use over time. The most common barriers include discomfort, problems with the mask, noise and a perceived lack of benefit. Eligibility (RCTs): - adult patients with OSA (AHI > 5/h) - allocation to CPAP in the intervention arm and an inactive control in the control group - follow-up time of at least 4 weeks - reportage of any CPAP adherence time Continuous Positive Airway Pressure Ventilation | null |
CRD420250598063 | Does the use of gabiroba extract improve metabolic and inflammatory parameters in Wistar rats compared to a control group? | Obesity. Diabetes Mellitus. Hepatic steatosis. Dyslipidemia. Rodents of both sexes and that evaluate the effect of gabiroba on biomarkers of obesity, diabetes, dyslipidemia, inflammation or hepatic steatosis. | Studies that did not treat gabiroba as a therapeutic agent |
CRD420250639240 | To identify and review published evidence on the clinical safety, efficacy and effectiveness of treatments for non-segmental vitiligo (NSV), in adults. | The focus of this review is vitiligo, specifically NSV also defined as bilateral or symmetrical vitiligo. Subtypes of NSV including acro-facial, mucosal, generalised/common, universal, mixed and rare forms will also be considered. Inclusion criteria: adult patients with nonsegmental/bilateral/symmetrical vitiligo are the focus of this review. Mixed populations of NSV and segmental vitiligo (SV) will be included provided that outcomes are stratified by vitiligo type; subtypes of NSV including acro-facial, mucosal, generalised/common, universal, mixed and rare forms will also be considered. Given that the definition of adults may vary between countries, all studies in adult patients including those under the age of 18 years will be included and tagged. Inclusion: pharmacological interventions including, as mono- or in combination therapy, topical corticosteroids (e.g. betamethasone, dexamethasone, methylprednisolone, prednisone, prednisolone, clobetasol propionate, hydrocortisone, triamcinolone, mometasone furoate), topical calcineurin inhibitors (e.g. tacrolimus and pimecrolimus), calcipotriol (topical vitamin D), systemic corticosteroids (e.g. betamethasone, dexamethasone, methylprednisone, prednisone, prednisolone, hydrocortisone, triamcinolone), immunomodulatory therapies (e.g. methotrexate, cyclosporine, azathioprine, apremilast), biologics (e.g. etanercept, infliximab, adalimumab, abatacept, secukinumab, ustekinumab, ixekizumab, brodalumab, bimekizumab, guselkumab, tildrakizumab, risankizumab, mirikizumab), topical kinase inhibitors (e.g. ruxolitinib), oral kinase inhibitors (e.g. tofacitinib, upadacitinib, baricitinib, deuruxolitinib, abrocitinib, delgocitinib, ritlecitinib), photo/light therapy (e.g. ultraviolet B [UVB], narrowband [NB]-UVB, psoralen with ultraviolet A [PUVA]), crisaborole (phosphodiesterase-4 [PDE4] inhibitor), melanocyte transplantation, laser (e.g. carbon dioxide or excimer), surgical techniques (e.g. mini punch grafting, suction blister grafting, split skin grafting, cellular grafting), and microneedling. Any comparator is permitted as long as the comparison includes at least one specified intervention of interest. | Exclusion: patients without vitiligo, with segmental/unilateral/localised/focal/unisegmental/bisegmental/plurisegmental vitiligo, or keloid or hypertrophic scars will be excluded. Paediatric, infant and non-human studies will also be excluded. Studies for which the patient age range is not specified or unclear will be tagged and considered for inclusion at full text review. Exclusion: herbal medications, cosmetic treatments, depigmentation techniques, other treatments not mentioned in the inclusion criteria unless in combination with a relevant intervention. |
CRD42024613787 | What is the effectiveness of Ascorbic acid/ Vitamin C in the treatment of Gingival hyperpigmentation? | effect of Ascorbic acid/Vitamin C in gingival hyperpigmentation patients | null |
CRD42023412320 | Reports will be evaluated using PICO (Population, Intervention, Comparison and Outcomes). We will evaluate the site of tendinopathy/enthesopathy, the type of embolic agent used, the change in symptoms with treatment, and adverse events. | Refractory tendinopathy | null |
CRD42024616154 | This umbrella review aims to address the overarching question:
What are the safety and efficacy profiles of Aducanumab, Lecanemab, and Donanemab for the treatment of Alzheimer’s disease, based on existing meta-analyses and supplementary evidence from trials and subgroup analyses not previously included?
To address this broad question, the review is divided into the following specific sub-questions:
Efficacy:
How do Aducanumab, Lecanemab, and Donanemab compare in terms of improving cognitive outcomes (e.g., ADAS-Cog, CDR-SB)?
What is their impact on Alzheimer’s disease biomarkers (e.g., amyloid plaque reduction, tau levels)?
Are there subgroup-specific differences in efficacy (e.g., APOE4 carriers vs. non-carriers, early vs. advanced stages of Alzheimer’s disease)?
Safety:
What are the rates and types of adverse events, including ARIA (amyloid-related imaging abnormalities), associated with each drug?
Are there differences in safety profiles across patient subgroups (e.g., APOE4 carriers, gender)?
Methodological Comparisons:
How do existing meta-analyses differ in their inclusion criteria, statistical methods, and handling of heterogeneity?
What are the methodological limitations of existing meta-analyses, and how do they affect the conclusions?
Supplementary Evidence:
What additional insights can be gained from trials, subgroup analyses, and real-world studies not included in previous meta-analyses? | Alzheimers disease | null |
CRD42024617388 | P (Population)
Population involved: Includes all individuals participating in the study, such as the general population, patients with hypertension, etc. (specific details need to be obtained from the study).
I (Intervention)
Intervention: Different levels of salt intake (low-salt diet or reduced salt consumption).
C (Comparison)
Comparison group: Higher levels of salt intake (high-salt diet or normal intake).
O (Outcome)
Outcome: Changes in blood pressure (such as alterations in systolic and diastolic pressure). | This study focuses on the connotations and applications of salt in health preservation culture, integrating traditional Chinese medicine theories with modern science. It explores the health benefits, pathogenic effects, therapeutic roles, and medicinal uses of salt, while also extracting patterns through data mining. The aim is to promote the dissemination of salt health preservation culture and the prevention and treatment of diseases such as hypertension. | null |
CRD420251024072 | What is the landscape of somatic mutational signatures in Triple-Negative Breast Cancer and their implications for treatment response? | • TNBC ( all subtypes) of any age Patients with histologically confirmed Triple-Negative Breast Cancer (TNBC). Studies must differentiate TNBC from other breast cancer subtypes based on receptor status (ER-, PR-, HER2-). Randomized and non-randomized control studies, observational studies, retrospective as well as prospective cohort studies, case-control studies, genome sequencing studies published in English, which reported the somatic mutations associated with TNBC. Studies must report somatic mutations identified using Whole-exome sequencing (WES), or targeted next-generation sequencing (NGS) panels. Studies published within the last 10-15 years (based on the genomic technology advancements). Somatic mutation analysis using next-generation sequencing (NGS) methods like Whole Exome Sequencing (WES) and Targeted Gene Panels. | Literatures published in other than English language, non-human studies, non-experimental studies such as surveys, review articles, systematic review, meta-analysis, abstracts, conferences abstracts, posters, editorials, seminar presentations, unpublished material, commentaries, reviews, notes, guidelines, unavailable full-text articles, books and unpublished clinical trial related studies will be excluded from this study. Studies that focus only on germline mutations (e.g., BRCA1/2 hereditary mutations) without reporting somatic alterations as well as studies that report only epigenetic |
CRD42018096015 | To investigate whether a TCM formula named Tong Xin Luo in combination with atorvastatin shows more prominent therapeutic effects against coronary heart disease angina, and is associated with fewer adverse reactions, compared with atorvastatin treatment alone. | Coronary heart disease angina is mainly caused by coronary atherosclerotic stenosis caused by the supply of blood can not meet the needs of cardiac activity. | null |
CRD42023413188 | What are the regional differences in prevalence of non-conventional cardiovascular risk factors amongst acute coronary syndrome patients without standard modifiable cardiovascular risk factors, and their effects on the patients' survival and prognosis? | Regional differences in non-conventional cardiovascular risk factors in acute coronary syndrome patients without standard modifiable cardiovascular risk factors, and their effects on survival and prognosis | null |
CRD420250640476 | Establish the value of physical therapist-led treatment and determine if the level of supervision and frequency of visits of this type of licensed clinician provided at any time over the two years following the diagnosis of frozen shoulder (adhesive capsulitis) affects terminal outcomes and resolution of function from the disease. | Frozen Shoulder; Adhesive Capsulitis; Supervision While Exercising; Physical therapy exercises; Physiotherapy; Manual Therapy; Physical Therapy Education; Physical Rehabilitation Therapy Procedure Primary adhesive capsulitis (frozen shoulder) is a diagnosis of exclusion, with an ill-defined ethology, in which there is an insidious onset of shoulder symptoms with a predictable and progressive loss of shoulder motion. We will track for included articles what criteria was used to make this diagnosis, what type of healthcare provider rendered the diagnosis and the type, if any, imaging that was used to screen or confirm its presence. Studies of adults between 18-80 years old with shoulder pain and restriction of active and passive range of motion, especially external rotation and/or specific diagnostic labels of adhesive capsulitis or frozen shoulder. If reported, subjects can be in any stage (freezing, frozen, or thawing) of the disease at inception. The study must report a patient-reported outcome and/or pain value as a measured variable. Physiotherapy; Manual Therapy; Exercise therapy; Patient Education; Electrotherapy; Ultrasound therapy; Dry needling; Graded Exercise Therapy; Thermotherapy; Multi-modality Physical Therapy System The dependent variable will be the frequency and type of interventions delivered by licensed/credentialed physical therapist or physiotherapist. The intent is to evaluate the value of supervised physical therapy visits as compared to independent, self-management strategies that can be provided for the patient without access to a physical therapist or with an alternative healthcare provider. Given adequate frequency of specific treatment strategies such as passive stretching, manual therapy, exercise (strength) training, physical agents, or electrotherapeutic modalities, these interventions will be independently subanalzyed. These patients would have had at least three formal encounters (visits) with a licensed healthcare provider to assist in their recover over a one-year period. PICO tags selected: Usual Care The alternative intervention is characterized as "watchful waiting" or "supervised or benign neglect". This describes management in which the subject is provided medical advice, pathology education, prognostic information, home remedies, and therapeutic activities and exercises and activities that can be done without the inclusion or oversight of a licensed healthcare provider. These patients will not have interactions (visits) regarding their shoulder injury over the course of two years with a physical therapist. | Onset of shoulder pain and/or stiffness that has a clear history of trauma or joint disease (i.e. rotator cuff tear, fracture, dislocation, arthritis), post-surgical stiffness from surgery in previous six months, neurological, endocrine, metabolic, cardiovascular, or cognitive medical disorders Interventions not provided by a licensed/credentialed physical therapist or physiotherapist will be excluded |
CRD42022320270 | To explore current treatment options for patients with diabetic retinopathy after undergoing cataract surgery. To discuss the efficacy of anti-VEGF drugs, nonsteroidal drugs, and steroids for patients undergoing cataract surgery in patients with pre-existing diabetic retinopathy. | Diabetic retinopathy is currently a major cause of vision threat in diabetic patients and one of the main diseases that cause blindness in diabetic patients. The population of patients with diabetic retinopathy who also have cataracts is a gradually expanding group of patients, of which there are many factors that lead to the progression of diabetic retinopathy, and the impact of cataract surgery should not be underestimated. The inflammatory stimulation brought about by cataract surgery can lead to the progressive invasion of diabetic retinopathy after surgery. Currently, the main therapeutic drugs include anti-VEGF drugs, non-steroidal drugs and steroids, but there is still controversy about the best treatment option. | null |
CRD420251031657 | What is the efficacy and safety of sotatercept compared to standard care or placebo in patients with pulmonary arterial hypertension? | Adults with pulmonary arterial hypertension (PAH) Treatment with sotatercept PICO tags selected: Placebo; Usual Care | null |
CRD42023482414 | What are the effects of vitamin D supplementation in women of childbearing age with polycystic ovary and insulin resistance? | Vitamin D in Polycystic Ovary Syndrome and Insulin resistance. Women of childbearing age with a diagnosis of Polycystic Ovary Syndrome and insulin resistance Effects of vitamin D supplementation in women of childbearing age with Polycystic Ovary Syndrome and insulin resistanceInclusion criteria:Clinical trials, observational studies published in English. Studies carried out in women between 20-40 years old.Studies carried out in patients with a diagnosis of PCOS and IR either.Studies containing complete data on vitamin D levels in women of childbearing age.Exclusion criteria:Research in pregnant patients. Studies carried out outside the American continent. Studies with less than 50 participants.Studies in patients with comorbidities that affect vitamin D synthesis. Effects of vitamin D supplementation with placebo. | null |
CRD420250491639 | Question and strategy: PICOCP: in vivo and clinicalI: Natural productsC: Natural therapy compared to placebo, other treatment or no treatment, given at any dose or concentration, duration, and regimenO: Biological effects of natural products on reduction of DRGE in models experimentalsC: Esophagus | Gastroesophageal reflux disease (GERD) is a prevalent condition that affects approximately 20% of the western population. Therapeutic alternatives must be considered, since 30% of patients do not respond adequately to the gold standard therapy (Proton Pump Inhibitors). In this sense, herbal medicines have been proposed as a useful alternative, where the field of research of GERD began to look for products of natural origin for the treatment and/or prevention of this condition. Inclusion: individuals diagnosed with Gastroesophageal Reflux Disease. Interventions to study Gastroesophageal Reflux Disease at a population level are defined as those applied to a group of people who have some of the classic symptoms of that pathology, such as heartburn, for example, and which affects the majority of overweight people. Changing the lifestyle of these patients appears to be an important factor in making them less prone to reflux disease. These are approaches that depend mainly on the clinical condition of each of the groups studied.Examples include replacing processed foods with fresh foods, using natural products, reducing the consumption of soft drinks, caffeine, improving quality of life with physical exercise and sports. Such approaches could also be part of broader interventions and risk warning compromising the health of those with GERD. Inclusion: individuals with GERD using a natural product | Exclusion: individuals who do not have Gastroesophageal Reflux Disease. Exclusion: individuals without GERD |
CRD420251018579 | This systematic review and meta-analysis aim to compare Berdazimer Sodium and Cantharidin in terms of their safety profiles and efficacy in treating MC. | 1. Study should be randomized placebo controlled trials. 2.Patients of any age diagnosed with Molluscum Contagiosum. 3.No restriction on publication year to capture all relevant studies. Monitoring For Signs And Symptoms Of Infection The intervention/exposure that is considered to be reviewed: Drugs like Berdazimer sodium and Cantharidin helps in the complete clearance of MC lesions in the patients with Molluscum contagiosum. Inclusion criteria: 1.Drugs including Berdazimer sodium and cantharidin for the treatment of Molluscum contagiosum. PICO tags selected: Cantharidin Placebo as per the study design Inclusion criteria: 1. Study should be randomized placebo controlled trials. | 1. Studies that are not randomized. 2. Studies that uses control/comparison other than placebo 3.Case reports, case series with fewer than 10 patients, narrative reviews, expert opinions, and editorial articles. 4.Animal studies, in vitro studies, and preclinical trials. Exclusion criteria: 1. Drugs like Berdazimer sodium and Cantharidin which are treated for conditions other than Molluscum contagiosum 2. Drugs like Berdazimer sodium and Cantharidin which are treated for symptoms other than complete clearance of MC lesions . other than placebo are excluded Exclusion criteria: 1. Studies that are not randomized. 2. Studies that uses control/comparison other than placebo |
CRD420251021722 | 1. To explore the effectiveness of parent-mediated interventions for children with ASD in LMICs from parents' perspectives | Parents or caregivers of children diagnosed with ASD. Patient-mediated intervention; Parenting Education; Caregiver Support; Cognitive Behavioural Therapy Parenting Programme This review will include qualitative studies such as interview studies, focus group discussions, ethnographic research, and other studies using qualitative methodologies to explore parental experiences. | Participation in parent-mediated interventions, defined as structured behavioural, educational, or therapeutic programmes delivered by parents or caregivers with professional guidance. Quantitative studies, mixed-methods studies, reviews, editorials, opinion pieces, and studies not focusing on parent or caregiver experiences will be excluded. |
CRD42021234520 | Is physiotherapy effective for the improvement of patients with temporomandibular disorders? | Temporomandibular disorders. Physiotherapy. | null |
CRD42023449782 | evaluate the efficacy and safety of yiqifumai injection in the treatment of heart failure complicated by ventricular arrhythmia | A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION. | null |
CRD42023388875 | By means of systematic review and meta-analysis, this study explored the clinical efficacy of "invigorating qi and nourishing Yin and promoting blood circulation" in the intervention of diabetic nephropathy. The intervention measures of the control group were ACEI or ARB drugs, and the observation group was combined with traditional Chinese medicine with invigorating qi and nourishing Yin and promoting blood circulation on the basis of the intervention measures of the control group. We observe whether there are significant differences between the two groups in improving blood glucose index, renal function index, inflammatory factor index, oxidative stress index, lipid index, endothelial function index and renal fibrosis index, so as to speculate the clinical efficacy of "Qi nourishing Yin and activating blood circulation method" in the intervention of diabetic nephropathy, and provide a new treatment plan for the clinical treatment of diabetic nephropathy. | In 2021, the prevalence rate of diabetes among people aged 20-79 in the world will be 10.5% (536.6 million people), which is expected to rise to 12.2% in 2045. In recent years, Chinese medicine has achieved excellent results in improving DN symptoms, assisting in stable blood pressure lowering, blood sugar lowering, blood lipid lowering, improving renal function, and preventing disease progression. In recent years, numerous data have proved that the method of supplementing qi, nourishing yin and activating blood circulation has a excellent effect in the treatment of DN with deficiency of both qi and yin and blood stasis. However, due to the different observation outcome indicators, uneven research quality, and small sample size, it is difficult to provide reliable guidance for clinical practice. Therefore, the author collected the clinical trials of the method of supplementing qi, nourishing yin and activating blood circulation to intervene in DN with deficiency of both qi and yin and blood stasis, and conducted systematic evaluation and meta-analysis to provide a reliable evidence-based basis for the clinical application of the method of supplementing qi, nourishing yin and activating blood circulation in DN with deficiency of both qi and yin and blood stasis. | null |
CRD420250652683 | There is increasing interest in the potential benefits of circuit class training after stroke, but its effectiveness is uncertain. | Stroke is one of the leading causes of impairment and disability in the world. The activity most affected by stroke is walking with as many as 80% of patients initially losing this ability.Stroke rehabilitation improves
walking competency in terms of gait and gait-related activities, although most individuals are still significantly disabled beyond 6 months after stroke. | null |
CRD42024569830 | Population: Patients suffering from Oral precancerous lesions
Intervention: Phytochemicals used as therapeutic agents in prevention of OPMD
Comparison: Traditional therapy ex., Surgical, multivitamin or other drugs, another group of phytochemicals
Outcome: Clinical, Pathological or molecular changes in lesions | A lesion with a predisposition to malignant transformation is called potentially malignant disorder. Premalignant disorder of oral mucosa are the diseases that have malignant transformation risk at different ratios. Whereas Oral Squamous Cell Carcinoma originates from premalignant disorder of the oral cavity. | null |
CRD42022353739 | The aim of this meta-analysis of randomized controlled trials is to evaluate the efficacy and safety of traditional Chinese exercise in the treatment of chronic fatigue syndrome to provide a basis for guiding further treatment. | Chronic fatigue syndrome (CFS) is a group of nonspecific systemic diseases with recurrent fatigue episodes for at least 6 months and accompanied by a variety of physical and mental discomfort symptoms. According to relevant epidemiological statistics, the global prevalence of CFS is 0.4%-2.5%, with a high incidence in young and middle-aged people aged 20 to 40 years. At present, western medicine treatment for CFS mainly includes nutritional support, drug therapy, psychological intervention, etc., but long-term use has side effects and dependence, and little efficacy. Complementary and alternative medicine has significant advantages over western medicine because of its low cost, high efficiency and few side effects. Traditional Chinese exercise (TCE), as a therapeutic, Aerobic, and mind-body exercise originated from traditional Chinese medicine tracing back to approximately three thousand years ago. More and more RCTs have indicated that TCE can significantly improve the symptoms of CFS. However, results of different trials are inconsistent due to the small sample size, short duration time, and the severity of CFS in participants. Therefore, it is appropriate to further investigate the effectiveness of TCE for patients with CFS, aiming to help doctors and other health-care professionals plan stage-specific treatment for patients. | null |
CRD42022304170 | The aim of this network meta-analysis of randomized controlled trials is to to estimate and rank the relative efficacy of immunotherapy according to the PD-L1 statute for advanced melanoma. | Malignant melanoma is the most aggressive type of skin cancer with invasive growth patterns. Traditional methods like surgery, radiation therapy, and chemotherapy are not effective in the treatment of metastatic and advanced melanoma. However, the use of immune checkpoint blockade has revolutionized the treatment of advanced melanoma, with dramatic improvements in cancer-related outcomes since the advent of these agents. Antibodies targeting the PD-1 axis have shown enormous potential in the treatment of metastatic melanoma. Nevertheless, despite the successes of front-line immune checkpoint inhibitor therapy, most patients will eventually progress. The development of predictive biomarkers is needed to optimise patient benefit, minimise risk of toxicities, and guide combination approaches. The greatest focus has been on tumour-cell PD-L1 expression. However, the prognostic value of PD-L1 expression in melanoma is still controversial. Controversial results have been observed regarding the clinical utility of PD-L1 expression for immune therapies in advanced melanoma. The objective of this research is to perform a network meta-analysis (NMA) in previously untreated melanoma patients and estimate the relative efficacy of immune therapies based on PD-L1 expression status for this patient population at the therapeutic level. | null |
CRD420251003838 | What are the specific neural correlates of hypnotic analgesia? Do the neural correlates of hypnotic analgesia vary in different conditions, e.g., in experimental versus clinical or acute versus chronic applications? | People participating in hypnotic analgesia studies. Eligibility criteria: Studies including hypnotic pain modulation interventions meeting the following criteria: 1. The intervention used in the study is labelled by the authors as "hypnosis" (or "hypnotic treatment", "hypnotherapy", etc.) AND is veritably acceptable as a bona-fide hypnotic procedure; 2. Hypnotic reduction of pain (hypnoanalgesia) OR hypnotically induced, enhanced, or modified pain is present in the study; 3. There is a neuroimaging procedure utilized (PET, fMRI, MEG, etc.) 4. In the event that the study is a clinical intervention, it is imperative that it utilize no more than one form of treatment in order to measure the individual effects of specified interventions. Brain activation patterns will be compared to the baseline utilized in each study. With the pain neuromatrix being an inherent component of hypnoanalgesia, region-specific activation in the brain related to hypnosis and pain are assumed to merge, as the two phenomena act in tandem. This necessitates that in the control condition a non-hypnotic pain modulation procedure be used in order to account for the pain-relieving properties of hypnotic analgesia. We will only include studies which applied such controls; studies exclusively utilizing wakeful rest and kindred controls will not be included in our meta-analysis. Experimental studies will be included. | All single-subject studies and case series will be excluded. |
CRD42023455712 | The primary aim of this meta-analysis is to investigate the therapeutic effects of iCBT compared to non-active controls on binge spectrum disorders | Binge spectrum disorders include mental disorders primarily characterized by recurrent episodes of binge eating, specifically referring to, bulimia nervosa (BN) and binge eating disorder (BED).Binge spectrum disorders exert a notable influence on a significant portion of the population. According to a recent systematic review, the lifetime prevalence rates are reported as 0.63% for BN and 1.53% for BED. Furthermore, research has highlighted a remarkable increase in the worldwide occurrence of eating disorders during the previous decade. Considering the profound effects of the global COVID-19 pandemic, these figures might be even higher than expected.Cognitive Behavioral Therapy (CBT) stands out as the most effective treatment method for treating binge spectrum disorder.Nevertheless, obstacles such as elevated treatment expenses and extended therapy durations impede patients' access to standardized treatment.Internet-based Cognitive Behavioral Therapy (iCBT) emerges as a method that applies CBT principles while simultaneously providing patients with access to structured treatment plans from the convenience of their own homes.Currently, some studies have applied iCBT to binge spectrum disorders to observe its therapeutic efficacy. However, due to differences in research designs and sample sizes among studies, there remains a scarcity of precise and consistent conclusions. | null |
CRD420250641380 | What is the role of extracellular vesicles (EVs) in the pathogenesis, diagnosis, and treatment of endometriosis, and how can EV-derived biomarkers and engineered EVs be harnessed for non-invasive diagnosis and targeted therapeutic interventions in this disease? | Endometriosis is a chronic, inflammatory gynecological disorder in which endometrial tissue, which normally lines the uterus, grows outside the uterine cavity. This ectopic tissue can implant on various organs within the pelvic cavity, including the ovaries, fallopian tubes, and the tissue lining the pelvis. In rare cases, endometrial tissue may also be found beyond the pelvic region.The primary symptom of endometriosis is pelvic pain, which can manifest as severe menstrual cramps, chronic lower back and abdominal pain, or pain during sexual intercourse. Other symptoms include heavy menstrual bleeding, irregular periods, fatigue, and infertility.Endometriosis affects approximately 10% of reproductive-aged women and can significantly impact their quality of life. Despite its prevalence, the exact cause of endometriosis remains unknown, and current treatment options are limited to managing symptoms and improving fertility outcomes. As a result, understanding the complex pathophysiology of endometriosis and exploring novel therapeutic approaches remain crucial areas of research in women's healthcare. Studies involving animal models related to endometriosis.Studies providing sufficient data on extracellular vesicles (EVs) and their involvement in endometriosis.Species:Primarily animal models (n=10) were included, which can provide valuable insights into the pathophysiology of endometriosis and inform future research.Details of disease model:The focus of the selected studies was on the role of EVs in endometriosis, exploring their involvement in the pathogenesis (n=39), potential as biomarkers (n=37), and therapeutic strategies (n=31). These studies help to deepen our understanding of the complex mechanisms underlying endometriosis and the potential utility of EVs in diagnostics and targeted therapies. The reviewed studies focused on the roles and applications of extracellular vesicles (EVs) in endometriosis. The interventions and exposures explored in these studies revolved around the involvement of EVs in endometriosis pathogenesis, their potential as diagnostic biomarkers, and their utility in therapeutic strategies.Inclusion criteria:Studies investigating the role of EVs in the pathogenesis of endometriosis.Studies examining the potential of EVs or their cargo (e.g., miRNAs, proteins) as diagnostic biomarkers for endometriosis.Studies exploring the therapeutic applications of EVs, engineered EVs, or their cargo in endometriosis treatment.Nature of interventions/exposures:Studies examining the pathogenesis of endometriosis focused on the involvement of EVs in immune modulation, epithelial-to-mesenchymal transition (EMT), angiogenesis, and fertility impairment.Studies investigating diagnostic biomarkers analyzed EV-derived molecules, such as miRNAs and proteins, which could serve as non-invasive markers for endometriosis diagnosis and disease monitoring.Studies exploring therapeutic strategies investigated the potential of engineered EVs or their cargo in targeting disease-specific pathways in endometriosis, paving the way for novel targeted therapies. | Studies lacking adequate information or data on EVs in endometriosis.Duplicate publications (if duplicates were found, only the most recent or comprehensive version was included). Exclusion criteria:Studies that do not focus on EVs, their cargo, or their role in endometriosis.Duplicate publications (if duplicates were found, only the most recent or comprehensive version was included). Exclusion criteria:Studies without appropriate control groups or comparisons.Duplicate publications (if duplicates were found, only the most recent or comprehensive version was included). |
CRD420250655998 | To explore the correlation between the prognosis of patients with hepatocellular carcinoma undergoing transarterial embolization chemotherapy and the levels of inflammatory factors such as plr and nlr that are either high or low | Study patients were diagnosed with localized Hepatocellular carcinoma patients diagnosed with localized Hepatocellular carcinoma transarterial embolization chemotherapy (Monotherapy or Combined therapy) Experimental group: High expression of inflammatory factors; Control group: Low expression of inflammatory factors. | null |
CRD420250643232 | Do socio-demographic, psychological, lifestyle, clinical or biological factors predict the treatment response in adult patients with treatment-resistant depression? | Treatment-resistant depression is a variably defined term in psychiatric care and research for non-response of a major depressive episode to antidepressant treatment. A consensus definition does currently not exist. • Patients with uni- or bipolar major depressive episode according to ICD-10 or DSM-4/ DSM-5 characterized as treatment-resistant• Age ≥ 18 years Predictors for response to any antidepressant treatment in treatment-resistant depression including socio-demographic, clinical, psychological, life-style or biological factors are the focus of this review. Any intervention to reduce depressive symptoms will be included. Not applicable | • Diagnosis of schizophrenia, schizoaffective disorder, postnatal depression, mental retardation • Age ≤ 18 years |
CRD42024567969 | What psychological interventions have been shown to enhance moral reasoning?
What are the English language-based interventions most effective for enhancing moral reasoning?
What are the key intersections between psychological and English language-based interventions that foster moral reasoning in individuals? | This systematic review focuses on the intersection of moral reasoning and English language skills in educational contexts. Moral reasoning, which involves the ability to discern right from wrong and make ethical decisions, is a crucial aspect of adolescent development. English language skills, encompassing reading, writing, speaking, and listening, are fundamental for academic success and effective communication. The review explores how English language instruction addresses and develops moral reasoning. It examines the psychological, moral and English language strategies used to empower moral reasoning, the impact of these approaches on students' moral and linguistic development, and the role of cultural and contextual factors in shaping these outcomes. This review seeks insights into effective practices by synthesizing the available evidence. | null |
CRD420250645001 | What is the efficacy, safety, and metabolic impact of Imeglimin in adults with Type 2 Diabetes Mellitus (T2DM) compared to standard glucose-lowering therapies? | Type 2 Diabetes Mellitus (T2DM) and the therapeutic role of Imeglimin in glycemic control, insulin resistance, weight management, and cardiovascular risk factors. Participants:Adults (≥18 years) diagnosed with T2DM.No restrictions on gender, ethnicity, or disease duration. Imeglimin, as monotherapy or in combination with other antidiabetic agents. Placebo or standard glucose-lowering therapies (e.g., metformin, sulfonylureas, GLP-1 receptor agonists, SGLT-2 inhibitors, insulin). | null |
CRD42023390367 | Pregnancy-related hyperemesis gravidarum is characterized by extreme nausea and vomiting. It may result in consequences like malnutrition and dehydration. There is some evidence that suggests gut dysbiosis, or an imbalance of gut bacteria, may have a role in the emergence of hyperemesis gravidarum. More research is required to ascertain the particular nature of the association between gut dysbiosis and this illness, as it is not yet fully known. Therefore, this systemic review will attempt to assess the state of the literature on the relationship between Hyperemesis gravidarum (HG) and changes that occurs in gut microbiota of mothers and assess if there’s any impact and association with any kind of complications during antenatal and postpartum pregnancy. | Hyperemesis gravidarum is a severe form of nausea and vomiting that can occur during pregnancy. It can lead to weight loss, dehydration, and other complications. Some research suggests that the gut microbiome may play a role in the development of hyperemesis gravidarum.
One study found that women with hyperemesis gravidarum had a different composition of bacteria in their gut microbiome compared to healthy pregnant women. Specifically, the bacteria in the gut microbiome of women with hyperemesis gravidarum were less diverse and had a higher proportion of Proteobacteria. This is an interesting finding, but more research is needed to understand the exact relationship between the gut microbiome and hyperemesis gravidarum | null |
CRD42023444363 | What are the characteristics of AI applications on real-world data (RWD) for uncontrolled and single-arm trials with external comparators or benchmarks for all indications, published in the period from 2010-2021? | Real-world data. Artificial Intelligence. Drug approval lifecycle. Uncontrolled trials. | null |
CRD42022334431 | What are the Managerial Barriers and Facilitators to Horticultural Therapy for the Wellbeing of People with Dementia in Care Settings?
P: people with dementia
I: effective management of horticultural therapy in care settings
C: non-effective management of horticultural therapy in care settings
O: improved wellbeing
S: Systematic Review and Meta-Analysis | The World Health Organisation (WHO) has designated dementia as a public health priority in 2012 (WHO, 2012). Behavioural and Psychological Symptoms of Dementia (BPSD) and the side effects of their pharmacological treatment are the main reason for hospital admissions of People with Dementia (PWD) (Kales et al., 2012). Therapeutic gardens and Horticultural Therapy (HT), a safe and nonpharmacological treatment, have been proven to enhance the wellbeing of PWD and effectively treat BPSD (Murroni et al., 2021; Ng et al., 2021). Care organisations in the UK have been leading in establishing these projects. However, the managerial side, procedural and contextual factors of the transdisciplinary therapy seem to be an obstacle and demands further research (Jarrott and Gigliotti, 2010). Successful and sustainable projects consist of a combination of horticultural knowledge with experience in BPSD, non-pharmacological therapeutic approach and social care (Dementia Adventure K Pyke 2021, personal communication, 8 December). | null |
CRD42024545665 | Concussion, a form of mild Traumatic Brain Injury, impacts individuals globally and can have a significant effect on cognition and quality of life years after the initial concussion occurred. Cognitive assessment and rehabilitation has proven to be effective in analyzing the changes and supporting improvements in cognition for concussed individuals. Given the rise in the use of technology in health care, exploring the role of technology for cognitive assessments and rehabilitation is a logical next step.
The aim of this review is to analyze the currently available literature on the use of technology for the cognitive assessment and rehabilitation of individuals who have sustained a concussion. The review will report on (1) the areas of cognitive function (e.g., memory, attention etc.) studied, (2) the populations studied (athletes or the general concussion) (3) the effectiveness of the technology (therapeutic impact or quality of assessment) and (4) whether end-users were involved in the design of the intervention. In doing so, the review can also provide a clear understanding of the current gaps in literature and provide suggestions for future studies. | The review will focus on individuals who have sustained a concussion (mild form of Traumatic Brain Injury), where technology has been used for cognitive assessments and/or rehabilitation. | null |
CRD420251011135 | this study systematically evaluates the effects of aerobic exercise on the functional physical fitness rehabilitation of cardiovascular disease patients. | Patients diagnosed with cardiovascular disease clinically, in accordance with WHO standards. The interventions in the observation group included one or more forms of aerobic exercise. Aerobic exercise refers to endurance training primarily relying on aerobic metabolism during physical activity. Specific interventions included, but were not limited to, walking, jogging, joint exercises, and Tai Chi. PICO tags selected: Usual Care; Aerobic Exercise RCT. | The control group received conventional rehabilitation or routine education measures. |
CRD42020218818 | With the launch of targeted drugs, more and more patients receive a single targeted drug or a combination of targeted drugs treatment. Unfortunately, there was no head-to-head comparison among the targeted drugs to indicate their differences in efficacy and safety, which is still a problem whether is the best choice for patients with pulmonary arterial hypertension. Currently, a amount of clinical trials and meta analysis have provided valuable experience and suggestions for the selection of targeted drugs. However, it’s the variety of targeted drugs and the inconsistent quality of randomized controlled trials (RCTs) that makes the treatment choice of targeted drugs more complex. Therefore, our aim is to conduct a more comprehensive meta analysis, select high-quality randomized controlled trials(RCTs), take multiple intervention measures and extract more outcome indicators to evaluate the therapeutic efficacy and safety of targeted drugs, so as to solve the existing contradictions and provide more convincing evidence for clinical practice of pulmonary hypertension. | Pulmonary arterial hypertension (PAH) is classified as a group 1 pulmonary hypertension (PH) and is defined by mean pulmonary artery pressure ≥25 mmHg, pulmonary artery wedge pressure ≤15 mmHg and pulmonary vascular resistance >3 Wood units, in the absence of other causes of precapillary PH (such as lung disease, chronic thromboembolic disease and other rare diseases). For a definitive diagnosis of PAH, a hemodynamic assessment by right heart catheterization is required.Epidemiological survey in the West showed that about 15 people per million suffered from PAH. Most of them had fatigue, dyspnea, angina pectoris, hemoptysis, or even right heart failure. | null |
CRD42021240950 | What are the characteristics of and recommendations on the use of real-world data (RWD) for regulatory decision making based on uncontrolled and single-arm trials with external comparators or benchmarks submitted to the European Medicine Agency (EMA) and/or Food and Drug Administration (FDA) for all indications from 2015-2021?
What are the characteristics of and recommendations on the use of RWD based on uncontrolled and single-arm trials with external comparators submitted to selected European Health Technology Assessment (HTA) bodies for all indications from 2015-2021? | Real-world data. Drug approval methods. Regulatory review. Uncontrolled trials. | null |
CRD42023483921 | Chinese herbal injections (CHIs) have demonstrated notable therapeutic advantages in treating severe acute pancreatitis (SAP). Nevertheless, the selection among various types of CHIs and determining which offers the most effective outcomes remains a subject of ongoing debate. | Acute pancreatitis (AP) denotes an aberration in the activation of pancreatic enzymes, inducing digestive effects on the pancreas and adjacent organs, culminating in a condition characterized by acute local inflammation within the pancreas and histological destruction of acinar cells. While 80% of AP patients manifest solely local inflammatory lesions, displaying relatively mild symptoms necessitating short-term treatment for recovery, approximately 15-20% progress from these local lesions to systemic multi-organ dysfunction, denoted as moderate or severe AP (MSAP/SAP). This group of patients is responsible for 20-40% of AP-related mortality. | null |
CRD420251012150 | This study aims to evaluate the prognostic value of serum albumin levels and related nutritional index in predicting post-stroke cognitive impairment (PSCI) among stroke survivors (Population), compared to non-PSCI. | Patients with post-stroke cognitive impairment who received a serum albumin-related nutritional index test versus patients with post-stroke noncognitive impairment who received a serum albumin-related nutritional index test will be included. Albumin; Nutritional Assessment | null |
CRD420250656262 | 1st question: Shockwave therapy more effective than ultrasound therapy in improving pain, function, and overall treatment outcomes in adults with chronic lateral epicondylitis?
2nd question: Does combining shockwave or ultrasound therapy with conventional treatment enhance outcomes compared to their standalone use? | This review focuses on chronic lateral epicondylitis, commonly known as tennis elbow, a condition that causes persistent pain and reduced function due to overuse of the forearm extensor tendons. It is a frequent issue among adults, particularly those engaged in repetitive arm movements, whether through work, sports, or daily activities. The study aims to compare the effectiveness of shockwave therapy and ultrasound therapy in managing this condition, examining their impact both when used alone and in combination with conventional treatments. By analyzing available evidence, this review seeks to provide insights into the best therapeutic approach for improving pain relief and functional recovery in affected individuals. | null |
CRD420251002231 | Determining the association between HLA polymorphisms and hepatitis B infection outcomes | The general population of Iran Hepatitis B Virus; Hepatitis C Virus Studies that provide clear data on HLA gene polymorphisms and their association with the outcomes of hepatitis B and C viral infections. Reports will be considered eligible for inclusion in the study if they meet the following criteria: Observational studies, including cross-sectional, cohort, and case-control studies, that provide clear data on HLA gene polymorphisms and their association with the outcomes of hepatitis B and C viral infections. Studies conducted on the Iranian population published in English or Persian between 2000 and 2025. | Studies that do not provide clear data on the association between HLA polymorphisms and hepatitis B and C will be excluded from the study. Studies that do not provide clear data or have low scores in quality assessment will be excluded from the study. Review studies, meta-analyses, case reports, and letters to the editor are also excluded. |
CRD420251004804 | we aimed to report an additional case of pSFT and achieve the first comprehensive systematic review of published pSFT cases, and to integrat the end-to-end management of pSFT from preoperative diagnosis, treatment, and follow-up. | Included: primary solitary fibrous tumor of prostate; Surgical pathology confirmed; Published literature in English. The search terms were "solitary fibrous tumor" AND "prostate" ORThe inclusion criteria were pathologically confirmed primary solitary fibrous tumor of the prostate from published English literature. "prostatic" AND "mesenchymal tumor or cancer". And a secondary search through references was also performed. | Exclusion: duplicate publications; The pathology is not clear; Review or conference abstracts. Exclusion: duplicate publications; The pathology is not clear; Review or conference abstracts. |
CRD42025647829 | What mechanisms underlie Escherichia coli's resistance to tigecycline, carbapenem, and colistin? Which molecular pathways or novel pharmacological targets may be investigated to combat multidrug-resistant E. coli? | Multi-antibiotic Resistance; Drug Resistance; Biological agent; Escherichia infection The rise of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Escherichia coli strains, particularly those resistant to last-resort antibiotics like carbapenems, colistin, and tigecycline, poses a critical global health threat. Resistance is driven by complex interactions between chromosomal mutations, mobile genetic elements, and adaptive mechanisms like biofilm formation. This review addresses the urgent need to map resistance pathways and identify exploitable vulnerabilities (novel drug targets) to guide next-generation antimicrobial development. The population of interest includes Escherichia coli (E. coli) strains that exhibit resistance to carbapenems, colistin, and/or tigecycline. Genetic modifications, Phenotypic profiling, Changes in intracellular biochemical pathways during antibiotic resistance. 1.Susceptible parental strains or mutants with resistance genes knocked out.2.Non-resistant clinical isolates: Matched by source (e.g., UTI, bloodstream) to contextualize resistance prevalence. | null |
CRD42023465179 | P: Patients with bone metastasis
I：177Lu-labeled bisphosphonate
O: Bone pain palliation
S: prospective or retrospective study | Bone metastases are considered a major cause of morbidity and mortality in many cancer, deteriorating quality of life in patients with bone metastasis. Alleviating the bone pain is considered an key measure to improve the patients' quality of life. Radioradionuclide therapy shows variable degrees of success for bone pain palliation. Among them, 177Lu-labeled bisphosphonate may be a effective measure. The aim of this review is to analysis the effectiveness of 177Lu-labeled bisphosphonate for bone pain alleviation and its safety. | null |
CRD420251026714 | Review Objective | Inclusion Criteria: Patients of any age undergoing endovascular neurointerventions, including but not limited to: Mechanical thrombectomy Endovascular coiling Stent-assisted coiling Flow diverter placement Embolization for arteriovenous malformations or fistulas Carotid or vertebral artery stenting Studies involving procedures performed for both elective and emergency neurovascular conditions (e.g., ischemic stroke, aneurysm, AVM) Antibiotic Prophylaxis; Mechanical thrombolysis ; Endovascular coil embolization This review will include studies evaluating the use of systemic prophylactic antibiotics administered to prevent infections in the context of endovascular neurointerventions. The intervention must meet the following criteria: Purpose: Antibiotics must be given prophylactically, i.e., to prevent infection rather than to treat an existing one. Timing: Antibiotics may be administered pre-procedure, intra-procedure, or post-procedure, as long as they are explicitly intended for infection prevention related to the endovascular procedure. Route of Administration: Systemic routes only—intravenous (IV), oral, or intra-arterial. Procedures Covered: The antibiotic prophylaxis must be related to an endovascular neurointervention, including but not limited to: Mechanical thrombectomy Intracranial aneurysm coiling (with or without stent assistance) Flow diverter placement Arteriovenous malformation (AVM) or dural arteriovenous fistula (DAVF) embolization Intracranial stenting Comparison groups may include: No antibiotics Placebo Alternative prophylactic antibiotic regimens Studies involving single antibiotic regimens or comparisons of different drugs/durations/dosing protocols will be included, provided they meet the prophylactic intent criteria. PICO tags selected: Placebo; Usual Care Studies will be included if they compare prophylactic antibiotic use to one or more of the following comparator conditions: No prophylactic antibiotics: Patients undergoing endovascular neurointerventions without receiving any form of prophylactic antibiotic therapy. Placebo: Use of a placebo administered in place of antibiotics, where applicable. Usual care: Standard procedural protocols that do not include prophylactic antibiotic administration or where prophylaxis is selectively applied based on institutional policy. Alternative antibiotic regimens: Studies comparing different prophylactic antibiotic agents, doses, durations, or timing (e.g., single-dose vs. multi-dose; pre-procedural vs. peri-procedural). Timing variations: Studies that assess the impact of delayed or differently timed prophylactic antibiotic administration compared to early or standard timing. Comparators must relate to the same types of endovascular neurointerventions (e.g., thrombectomy, coiling, flow diversion) to ensure comparability of procedural context. Randomized Controlled Trials (RCTs) Non-randomized controlled trials Prospective cohort studies Retrospective cohort studies Case-control studies Comparative observational studies | Exclusion Criteria: Patients undergoing non-endovascular neurosurgical procedures (e.g., open craniotomy) Interventions outside the neurovascular system (e.g., peripheral vascular or cardiac catheterizations) Studies focusing solely on antibiotic treatment (rather than prophylaxis) or unrelated to neurointervention Animal studies The following interventions or exposures will be excluded from this review: Therapeutic use of antibiotics: Studies in which antibiotics are used solely for the treatment of active infections (e.g., meningitis, sepsis) rather than for prophylaxis. Non-systemic infection control methods: Use of topical antiseptics, local antibiotic application, or device coatings without systemic antibiotic administration. Non-endovascular procedures: Prophylactic antibiotic use in open neurosurgical procedures (e.g., craniotomy) or non-neurovascular interventions (e.g., cardiac catheterizations, peripheral vascular procedures). Prophylaxis unrelated to the neurointervention: Antibiotic prophylaxis for conditions unrelated to the endovascular neuroprocedure, such as dental prophylaxis or unrelated systemic infections. Unclear or unspecified antibiotic purpose: Studies that do not clearly state whether antibiotics were used for prophylaxis versus treatment. The following comparators will be excluded from this review: Comparators involving open neurosurgical procedures (e.g., craniotomy) or non-neurovascular interventions (e.g., cardiac or peripheral vascular procedures). Comparators unrelated to antibiotic use, such as comparisons of surgical techniques, anesthesia methods, or device types without any relation to prophylactic antibiotic administration. Comparators involving therapeutic antibiotic use only, where antibiotics are administered solely for treating active infections rather than for prevention. Studies lacking a defined comparator group, such as single-arm studies or those without a control or comparison intervention. Unclear comparator protocols, where the comparator arm does not clearly define the absence, type, timing, or purpose of antibiotic use. Case reports, case series, and conference abstracts without full data Narrative reviews, editorials, commentaries, and letters to the editor Animal studies Non-comparative studies |
CRD42022366294 | The aim of this meta-analysis is to compare the use effect of single layer or double Dartos Flap Layer in TIPU, through the complication rate, the cosmetic results and parents satisfaction and so on. Furthermore, we hope to provide a precise therapeutic option for children suffering hypospadia. | Hypospadias is a common congenital malformation referring to malpositioning of the external urethral meatus because of fusion failure of the urethral folds and foreskin on the ventral penis. The meatus may present with various degrees of malpositioning, insufficient development of the penile ventral tissue, ventral penile curvature (chordee), ventral urethral opening, and excess dorsal preputial skin as anatomical manifestations. The incidence is one in 300 live male births worldwide.
Surgery is the only curative treatment for hypospadias. The most widely used hypospadias repair is tubularized incised plate urethroplasty (TIPU), first introduced by Snodgrass in 1999. However, urethrocutaneous fistulas represent the most frequent complication. In an effort to reduce fistula formation and other complications, many strategies have been proposed. In 2005, Kamal published a double dartos flap(DDF) to protect the neourethra, affirming that DDF provides more protection against fistula development rather than a single flap. Since this date, other authors have reported their experience in covering the neourethra with a double layer of dartos tissue in TIP urethroplasty, with very similar techniques and excellent.
In order to statistically elucidate the efficacy of double dartos flap layer in tubularized incised plate urethroplasty, a meta-analysis of more RCT studies is needed. | null |
CRD42023447726 | What is the role of 2D facial photography in the prediction and evaluation of paitients with obstructive sleep apnea (OSA)? | Obstructive Sleep Apnea (OSA) is a prevalent sleep breathing disorder characterized by recurrent episodes of upper airway obstruction during sleep, resulting in disrupted breathing patterns and reduced oxygen intake. Recent research has shown a significant correlation between OSA and craniofacial morphology, highlighting the importance of evaluating facial structures in understanding the etiology and severity of the condition. Craniofacial morphology evaluation involves the examination of various anatomical features, such as jaw position, facial soft tissue dimensions, and upper airway dimensions, as they can influence the propensity for airway collapse during sleep. Traditionally, cephalometry has been the gold standard for assessing craniofacial morphology. However, advancements in imaging technology have brought forth the use of 2D facial photography as a non-invasive alternative. 2D photography can offer several advantages over cephalometry, including reduced radiation exposure, increased cost-effectiveness, and easier accessibility, making it an attractive option for routine clinical evaluations and large-scale research studies. Therefore, our aim is to perform a systematic review examining the efficacy and current use of 2D photography techniques in OSA craniofacial morphology. | null |
CRD42021290659 | Mitragyna speciosa, commonly referred to as kratom, is a tree indigenous to Southeast Asia. Kratom leaves contain psychoactive and potentially therapeutic alkaloids such as mitragynine, which is increasingly studied due to its ability to bind opioid, serotonin, dopamine, and adrenergic receptors to produce a wide range of effects.^1 Kratom has been used for decades in Southeast Asia for medicinal, cultural, and recreational purposes but is considered a novel substance elsewhere.^2 In the United States and Europe, kratom use is becoming more prevalent,^3;4 and people have reported using kratom to relieve chronic pain, self-treat withdrawal symptoms, manage mental health disorders, and reduce alcohol or other drug use.^5;6
The increasing prevalence of kratom use in the United States and Europe and its frequent comorbidities^7;8;9 suggest that clinicians are likely to encounter kratom users and should be familiar with its clinical presentations. The available literature is limited mostly to case reports with highly divergent descriptions of patient characteristics and clinical courses.^10;11;12
Accordingly, this systematic review will address the following questions:
What clinically relevant information do clinicians document on patients who report kratom use?
How do clinicians assess patients who report or present with kratom use, physical dependence (e.g., withdrawal, or use to avoid withdrawal), or kratom use disorder (KUD)?
What interventions have been made available to patients with kratom-related morbidities? What were the outcomes?
Finally, are there any differences in case reports from Southeast Asia compared to case reports from other regions (particularly the United States and Europe)? | This systematic review will examine all kratom-related clinical presentations of patients who are documented in published case reports as having used kratom at any point. Particular attention will be given to case reports for which kratom exposure or use is the most salient clinical feature (e.g., the target of assessment, diagnosis, or treatment) either by virtue of the kratom use itself (e.g., kratom physical dependence or KUD) or by virtue of kratom-related morbidities.
Our focus will be on the clinically relevant information reported by the healthcare provider. We are particularly interested in: patient characteristics; acute presenting characteristics; assessment, diagnosis, and treatment of the patient; and the criteria that clinicians use to diagnose a kratom-related morbidity (including kratom withdrawal or KUD). | null |
CRD420251012912 | Therefore, this study aims to compare the magnitude of placebo effects between non-invasive placebo acupuncture and superficial needling in the treatment of adult insomnia through a Bayesian network meta-analysis. By including relevant randomized controlled trials, this study will systematically evaluate the effects of these two placebo acupuncture methods on subjective sleep quality and objective sleep parameters in patients with insomnia. The findings will provide scientific evidence for the design of future acupuncture research. | Adults diagnosed with insomnia disorder based on standardized diagnostic criteria, including the Diagnostic and Statistical Manual of Mental Disorders (DSM) versions III, III-R, IV, IV-TR, and V; the International Classification of Diseases (ICD)-10; the International Classification of Sleep Disorders (ICSD) versions 1, 2, and 3; the Chinese Classification of Mental Disorders (CCMD) versions 2R and 3; or other recognized criteria. The included interventions are limited to manual acupuncture and electroacupuncture. PICO tags selected: Sham Acupuncture; Usual Care; Waiting list control Sham Acupuncture includes non-invasive sham acupuncture and superficial acupuncture. | Participants diagnosed with secondary insomnia, defined as insomnia resulting from psychiatric or physical comorbidities or caused by substances such as medications or alcohol. Examples include insomnia induced by conditions such as major depressive disorder, anxiety disorders, obstructive sleep apnea, and restless legs syndrome. Massage, moxibustion, ear acupoint plastering, and other similar interventions were excluded. |
CRD42023478105 | 3D Printed Brackets in Orthodontic Treatment. | Study patiens were use orthodontic treatment of brackets. | null |
CRD420250620748 | Comparison of the efficacy and safety of targeted biologic and synthetic therapies for active psoriatic arthritis. | Psoriatic Arthritis; Disease-Modifying Antirheumatic Drug; Biological Treatment; Targeted Therapy Psoriatic arthritis (PsA) is a chronic inflammatory disease with a variety of manifestations in joints, skin and other tissues. First-line treatment includes non-steroidal anti-inflammatory drugs, local corticosteroid injections for musculoskeletal symptoms and topical therapies for psoriasis. For patients who do not respond adequately to first-line treatments, systemic therapy with conventional synthetic disease-modifying antirheumatic drugs (csDMARD), treatment with anti-tumour necrosis factor alpha (iTNF) inhibitors and other biologic (bDMARD) and synthetic targeted therapies (stDMARD) is recommended. Despite the variety of available therapies and advances in the treatment of AP, effective therapeutic options are needed for patients who have experienced inadequate responses or intolerance to current therapies. Translated with DeepL.com (free version) Adult patients diagnosed with active psoriatic arthritis according to CASPAR criteria, with inadequate response or intolerance to conventional first-line treatments. Adalimumab; Infliximab; Etanercept; Golimumab; Certolizumab Pegol; Ustekinumab; Remtolumab (ABT122) ; Secukinumab; Ixekizumab; Brodalumab; Bimekizumab; Guselkumab; Risankizumab ; Tildrakizumab; Abatacept; Apremilast; Tofacitinib; Upadacitinib; Filgotinib; Brepocitinib Deucravacitinib PICO tags selected: Placebo; Adalimumab; Infliximab; Etanercept; Golimumab; Certolizumab Pegol; Ustekinumab; Remtolumab (ABT122) ; Secukinumab; Ixekizumab; Brodalumab; Bimekizumab; Guselkumab; Risankizumab ; Tildrakizumab; Abatacept; Apremilast; Tofacitinib; Upadacitinib; Filgotinib; Brepocitinib Deucravacitinib | Patients under 18 years of age. |
CRD42024538904 | To systematically evaluate the efficacy and safety of Transcranial Direct Current Stimulation (tDCS) in the treatment of attention deficit hyperactivity disorder (ADHD). | Transcranial direct current stimulation (tDCS) is a rapidly evolving non-invasive brain stimulation technique (NIBS) that has been widely used in adults with proven efficacy. Its application in pediatric neurodevelopmental disorders is increasingly expanding. Attention Deficit Hyperactivity Disorder (ADHD) is the most common neurodevelopmental disorder, significantly affecting patient's academic, social, and daily functioning. tDCS holds promise in ameliorating core symptoms and executive function deficits in ADHD patients, potentially inducing long-term effects through neuroplasticity modulation, garnering considerable attention. There are currently some studies exploring the therapeutic effect of tDCS on ADHD, but due to limitations in sample size, the current results are controversial. This study systematically retrieved and conducted a systematic review of randomized controlled studies on tDCS in the treatment of ADHD at home and abroad. | null |
CRD42024507041 | 1) What specific types of adaptations have been made to substance use interventions for LGBTQ+ individuals?
2) For whom within the LGBTQ+ community have adaptations been created?
3) What is the efficacy of adapted substance use interventions for LGBTQ+ individuals?
1. Catalogue the types of adaptations made to substance use interventions for LGBTQ+ adults according to the Cultural Treatment Adaptation Framework (CTAF; Chu and Leino, 2017).
2. Describe the age, gender identity, sexual orientation, and racial makeup of study samples to assess the specific subgroups of the LGBTQ+ community that are currently included within available research on LGBTQ+ adapted substance use interventions.
3. Appraise the efficacy of the adapted interventions by summarizing substance use symptom change across studies and delineating symptom change based on adaptation type from the CTAF.
4. Identify remaining gaps in the literature to be addressed in future research to create a comprehensive research agenda on culturally adapted substance use interventions among LGBTQ+ adults. | Substance use of any type | null |
CRD42024538961 | Context: Managing metastatic castration-resistant prostate cancer (mCRPC) presents significant challenges.
Objective: This systematic review and meta-analysis assessed the efficacy and safety of prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (PRLT) utilising lutetium-177 (177Lu) and actinium-225 (225Ac). | Prostate cancer (PCa) stands as the leading type of cancer among men in 112 countries and ranks as the second most diagnosed cancer in males globally, with an estimated 1.4 million new cases and 375, 000 deaths reported annually [1]. In the United States, it is the most prevalent cancer among men, representing 29% of all new cancer cases and the second leading cause of cancer-related deaths [2]. Similarly, in the United Kingdom, PCa is identified as the most common cancer in men, accounting for 24.3% of all cancer diagnoses in 2020 | null |
CRD42023438350 | Does omega-3 fatty acid supplementation demonstrate clinical efficacy as a treatment in patients with psychotic disorders? | Schizophrenia spectrum and other psychotic disorders as well as individuals with first-episode psychosis and at ultra-high-risk for psychosis. | null |
CRD42024563996 | Looking at repetitive transcranial magnetic stimulation and spinal cord stimulation, which technique is more effective in the treatment of motor dysfunction in the Parkinson's Disease patient population? | Parkinson's disease (PD) is a condition where patients experience significant impairments in movement due to the progressive loss of dopamine-producing neurons. Approximately 70-90% of Parkinson's patients suffer from motor dysfunction, characterized by symptoms such as tremors, rigidity, bradykinesia, and postural instability, which severely impact their quality of life. It affects a substantial portion of the aging population, with incidence rates increasing with age. Effective management of motor dysfunction in Parkinson's patients requires a multifaceted approach, including pharmacological treatments, surgical interventions, physical therapy, and lifestyle modifications, making it a complex and challenging condition to manage. | null |
CRD42018098953 | Primary review question: What is the effect of cortisol on:
a. Cognition in animal models for Alzheimer’s disease
b. Mood in animal models for psychiatric conditions
c. Glycosylated haemoglobin and fasting glucose in animal models for diabetes
d. Weight gain in animal models for obesity
Secondary review question:
What is the effect of 11β-HSD1 inhibitors on cortisol in animal models for:
a. Alzheimer’s disease
b. Psychiatric conditions
c. Diabetes
d. Obesity | We are interested in understanding hypercortisolism as implicated in the following disease areas : •Alzheimer's disease • Psychiatric diagnosis (anxiety, post-traumatic stress disorder, depression, schizophrenia and bipolar) • Obesity • Diabetes All animal models (all species, all sexes) with one of the following diseases: Alzheimer’s disease, psychiatric condition (anxiety or depression or psychosis or post-traumatic stress disorder), obesity, diabetes. Primary review question- cortisol
Secondary review question- Treatment with 11β-hydroxysteroid dehydrogenase type 1 inhibitors. All timings, frequencies and dosages of treatment are eligible for inclusion Vehicle-treated animals, sham-treated animals, animals undergoing no treatment at all | Ex vivo, in vitro and in silico models. Animal models of co-morbidities. Human studies (covered under a separate protocol) Concomitant treatment with other compounds alongside a 11β-hydroxysteroid dehydrogenase type 1 inhibitor. Healthy, naive animal |
CRD42018098982 | How are educational strategies and scenarios described in promoting and improving self-care and adherence to treatment in patients with heart failure? | Heart failure (HF) is the common final pathway of most heart disease, being one of the most important chronic clinical challenges in the health field (Freitas and Pushel, 2013). It presents clinical signs and symptoms characterized by the fatigue / dyspnea / edema triad, which affect the physical capacity to perform activities of daily living, as well as work, social and cognitive impairment, finally translating into a decline in quality of life.
More current data indicates that 6.5 million people in Europe, 5 million people in the United States and 2.4 million people in Japan suffer from (HF) and annually, 1 million new cases are diagnosed worldwide (Boisvert et al, 2015). The estimated prevalence is that this syndrome affects 26 million people worldwide, with a risk of developing the disease after age 45 at the ratio of 1: 5, that is, individuals of productive age. This entails an increase in the costs of the social security system and recurrent hospitalizations increase the expenses of health systems.
Among many factors that contribute to an episode of decompensation of HF and recurrent hospitalizations, is the lack of adherence to the prescribed therapeutic regimen, which includes the pharmacological and non - pharmacological part, that is, the change of lifestyle. The main goal for effective control of HF is for the patient to adhere to its treatment proposal, however, one of the main reasons for failure to achieve this goal is the low or deficient capacity of individuals to exercise their self-care (Qavam et al, 2017).
Heart failure patients have the capacity for self-care and adherence impaired by cognitive limitation, depressive symptoms, consequence of the poor quality of life of these patients, presence of multicomorbidities and poor confidence or low self-efficacy to perform self-care. This directly influences patients' adherence and interaction with health professionals, since it is a complex process that goes from adherence to and follow-up of prescribed treatment, including the involvement of patients in the definition of their care plan, the search for good and health, represented by changes in lifestyle that include attendance at consultations and greater control of medication (Silva et al, 2015, WHO, 2009).
Many studies developed on these strategies use self care and adherence to treatment as important outcomes to evaluate the intervention developed. It is necessary to know, however, the detailed strategies and scenarios of these interventions in promoting the improvement of the patient's ability to self-care.
Educational programs are important tools of the multiprofessional team specialized in the follow-up of patients with HF. However, there are limitations in identifying the best strategies and adequate scenarios, since the interventions are heterogeneous, as well as the profile of professionals involved, making it difficult to evaluate the results.
Thus, this review may direct health professionals working in specialized clinics to make decisions about the use of the best educational intervention and choose the best health scenario to achieve the self-care and adherence of heart failure patients. | null |
CRD42022332565 | Outcomes of Iliac venous stenting for iliac venous compression syndromes (clinical and procedural) | Patients with Iliac vein compression syndrome | null |
CRD42025634339 | In our bibliometric analysis, we found that China is leading in international collaboration, publication volume, and citation frequency, highlighting its prominent position in this field. Oncotarget was found to be the most commonly co-cited journal. Ochiya, Takahiro is the most cited author. The keyword burst map showed that “mechanisms”, “lung”, and “tumor suppressor” became the most influential keywords in 2024. “Messenger RNAs” was the keyword with the strongest burst, lasting from 2014 to 2018. Additionally, “serum exosomes”, “mechanisms”, “cisplatin resistance”, and “mesenchymal transition” were identified as trend topics for future exploration. In summary, exosome miRNA plays a crucial role in the development and progression of LC, with its mechanisms being complex and diverse. Exosome miRNA can serve as biomarkers for LC diagnosis, prognosis evaluation, and treatment prediction, offering new insights for LC treatment. This study is the first comprehensive bibliometric analysis of exosome miRNA in LC, summarizing the research status and future trends over the past two decades. The findings offer valuable resources and practical insights for scholars, highlighting key information and potential research frontiers for the coming years. | Exosomes, microRNA, Lung Cancer, Bibliometrics, Data Visualization | null |
CRD42021265550 | What is the effect of pharmacological targeting of PPARs on renal injury in animal models of kidney disease? | Acute kidney injury, chronic kidney disease, and acute-on-chronic kidney injury. All in vivo animal models of kidney disease, including models of acute, chronic, and acute-on-chronic experimental renal injury. Treatment with an agent which pharmacologically targets one or more PPAR as its primary mechanism of action, including the PPAR-alpha, PPAR-beta/delta, or PPAR-gamma receptors as well as agents targeting two or all three PPAR subtypes (ie, with dual and pan-PPAR activity). Presence of an age- and time-matched control group treated with placebo/vehicle. | All non-in vivo animal studies including:
Exclusively human studies
Exclusively in vitro, ex vivo, or in silico studies. Absence of treatment with an agent which pharmacologically targets one or more PPAR subtype as its primary mechanism of action.
Treatment with a drug which increases PPAR activity but which is not a specific ligand of one or more PPARs (ie, interventions that indirectly implicate PPARs as potential therapeutic agents for kidney disease will be excluded; only studies which examine agents with direct pharmacological activity at one or more PPARs as its primary mechanism of action will be included).
Absence of an age- and time-matched control group treated with placebo/vehicle.
Multi-modal pharmacological treatment with two or more agents, including therein an agent to increase PPAR activity, whereby unique effects of the PPAR-targeting pharmacological agent cannot be directly determined. Absence of an age- and time-matched control group treated with placebo/vehicle. |
CRD420250655620 | Through the network meta-analysis of vertical and horizontal bone regeneration between titanium mesh and different membranes, we also performed network meta-analysis through soft tissue defects, membrane exposure and other complications. | Alveolar bone defect can be divided into horizontal bone defect, vertical bone defect and mixed bone defect. Mixed bone defect is considered as the most complex bone increment type. Traditional barrier membranes (such as absorbable collagen membranes and non-absorbable polyteflon membranes) lack self-forming ability and are prone to collapse when subjected to the pressure of the covered soft tissue, making it difficult to maintain a stable space for the bone increment area. Because of its good mechanical properties, fixed support and good biocompatibility, titanium mesh can be used in bone increment surgery of mixed bone defects to achieve better repair results. Therefore, the research significance of this meta-analysis is to combine data from multiple small sample RCT and cohort studies through mesh meta-analysis to further comprehensively evaluate the therapeutic effect of titanium mesh and different barrier membranes on horizontal and vertical bone increment, and analyze the incidence of soft tissue defects, membrane exposure and other complications of titanium mesh and different barrier membranes. To provide a basis for clinical application of titanium mesh in patients with bone increment before implantation and to reduce complications. Implant surgery is required for healthy subjects with alveolar bone defects, regardless of gender or age. Titanium mesh and different membranes and bone filling materials are used in GBR. Titanium mesh is used in GBR, including conventional and 3D printing individualized titanium mesh, and different membranes, including absorbable and nonabsorbable membranes. | null |
CRD420250652815 | P (Population): Adult patients with axial spondyloarthritis (radiographic axial spondyloarthritis/AS and non-radiographic axial spondyloarthritis).
I (Intervention): Use of JAK inhibitors (Tofacitinib, Baricitinib, Upadacitinib, Filgotinib).
C (Comparator): Conventional DMARDs, other biologics, or placebo.
O (Outcome): Evaluation of MACE/thromboembolism (DVT/PE), overall mortality.
Secondary outcomes: Blood pressure, lipid profile, CRP/ESR, BMI, glycemic profile, and smoking status. | This meta-analysis aims to evaluate the cardiovascular risk associated with the use of Janus kinase (JAK) inhibitors in adult patients with axial spondyloarthritis (axSpA), including both radiographic and non-radiographic forms. Given the increasing use of JAK inhibitors (Tofacitinib, Baricitinib, Upadacitinib, Filgotinib) as therapeutic options for inflammatory rheumatic diseases, it is essential to assess their safety profile, particularly concerning major adverse cardiovascular events (MACE) and thromboembolism (DVT/PE). | null |
CRD42018102966 | How do camps specifically designed for overweight or obese children and adolescents impact their health-related quality of life or weight-related quality of life? | Childhood obesity and health-related quality of life. | null |
CRD420251021276 | Schizophrenia is a severe mental disorder characterized primarily by distorted perception of reality, persistent delusions and hallucinations, disorganized thinking, abnormal behavior, and negative symptoms such as emotional blunting and social withdrawal. Patients may experience ongoing cognitive difficulties, and their symptoms may cyclically worsen or remit. Treatment typically includes pharmacotherapy, psychosocial interventions, and rehabilitation training, aimed at alleviating symptoms, preventing relapses, and assisting patients in regaining their social functioning. This study aims to apply Social Cognitive Interaction Training (SCIT) to the therapeutic outcomes of individuals with schizophrenia, with the intervention group receiving SCIT (a structured psychosocial intervention targeting social cognition and interpersonal functioning), the control group receiving conventional treatment, the outcome variable being a continuous variable (e.g., symptom severity or functional improvement), and the research method being a randomized controlled trial. | In this review, participants were all patients with schizophrenia, with the following inclusion criteria: (1) patients diagnosed with schizophrenia; (2) capable of completing various questionnaires and cognitive function tests; (3) patients or their family members sign an informed consent form after understanding the purpose and methods of the study; (4) patients aged 18 and above. Cognitive training Inclusion criteria for interventions should specify that the social cognitive interaction training (SCIT) must be explicitly described as targeting core domains of social cognition (e.g., emotion recognition, theory of mind, attributional bias) through structured therapeutic interactions. Interventions may include components such as group-based cognitive exercises, psychoeducation, role-playing scenarios, social problem-solving tasks, or video-based social cue analysis. Studies must involve active therapeutic engagement between participants and trained facilitators, with a minimum intervention duration of 4 weeks to ensure adequate exposure. Both standalone SCIT programs and those integrated with routine care are eligible. Comparators may include treatment-as-usual, other psychosocial interventions, or passive control groups. Exclude interventions combining SCIT with concurrent cognitive-behavioral therapy or pharmacological trials unless effects can be isolated. Include studies delivering SCIT in inpatient, outpatient, or community settings via face-to-face or hybrid formats. Training fidelity must be documented through manuals or protocol adherence checks. PICO tags selected: Usual Care (1) patients diagnosed with schizophrenia; (2) capable of completing various questionnaires and cognitive function tests; (3) patients or their family members sign an informed consent form after understanding the purpose and methods of the study; (4) patients aged 18 and above Randomized controlled trial | Exclusion criteria: (1) those with severe physical illnesses; (2) presence of cognitive or intellectual disabilities, or other serious mental illnesses; (3) individuals with self-harm, suicidal, or serious violent behaviors towards others. Exclusion criteria for interventions or exposures will involve studies that do not primarily focus on social cognitive interaction training grounded in positive psychology principles. Interventions will be excluded if they solely rely on pharmacological treatments, biological interventions (e.g., electroconvulsive therapy, transcranial magnetic stimulation), or non-interactive psychoeducational approaches without active participant engagement (e.g., passive health manual distribution without guided discussion). Studies emphasizing conventional cognitive-behavioral therapy without integrating social interaction components or positive psychology elements (e.g., strengths-based strategies, therapeutic alliance building, or role-playing to enhance self-awareness) will also be excluded. Additionally, interventions delivered exclusively in individual settings without group-based social interaction opportunities or those lacking structured activities to foster interpersonal skills and emotional reciprocity will be excluded. Interventions targeting non-psychotic disorders or mixed populations without separate schizophrenia data analysis will not be considered. (1) those with severe physical illnesses; (2) presence of cognitive or intellectual disabilities, or other serious mental illnesses; (3) individuals with self-harm, suicidal, or serious violent behaviors towards others. |
CRD42025642010 | The aim of this review is to describe the patients post-lung transplant with the outcome of altered airway protection confirmed by objective assessment. | Lung transplantation is considered a therapeutic intervention for those with disease processes which result in end-stage lung disease and respiratory failure. Patients post-lung transplant are acutely at risk for oropharyngeal swallowing impairment and aspiration. Abnormal swallowing and aspiration as a consequence could be dire in the immunosuppressed post-lung transplant population. Given the surgical risk factors related to lung transplant, abnormal swallowing may be covert post-transplant and the incidence, risk factors, and overall nature of swallowing impairment post-lung transplant remains poorly understood.Therefore, this review seeks to investigate the evidence which reports abnormal airway protection as an outcome post-lung transplant. | null |
CRD420250652675 | What is the safety and efficacy of Cimlanod (Nitroxyl donor) in Heart failure with reduced ejection fraction? | Heart failure (HF), a leading cause of morbidity and mortality worldwide, continues to pose a therapeutic challenge despite advancements in pharmacological and device-based treatments. Nitroxyl (HNO) donors, including cimlanod (BMS-986231), are emerging as promising agents due to their unique vasodilatory, inotropic, and lusitropic properties. This meta-analysis synthesizes evidence from four pivotal studies investigating the safety, efficacy, and hemodynamic effects of cimlanod in Heart failure with reduced ejection fraction (HFrEF) populations, aiming to clarify its clinical potential and limitations. | null |
CRD42023424511 | What is the effectiveness and safety of the therapeutic agent CRLX10 in the treatment of various types of cancer, and how does it compare to conventional treatments and other therapeutic agents, considering factors such as overall survival, progression-free survival, quality of life, toxicity profiles, and the occurrence of adverse events in clinical studies? | Cyclodextrins are a family of cyclic oligosaccharides composed of glucose molecules linked by α-1, 4 glycosidic bonds. They are known for their ability to form inclusion complexes with various guest molecules, enhancing the solubility, stability, and bioavailability of these molecules.
Cancer is a complex group of diseases characterized by the uncontrolled growth and spread of abnormal cells. It is a leading cause of death worldwide, with numerous types and subtypes, each with unique molecular and cellular characteristics. Conventional cancer treatments, such as surgery, chemotherapy, and radiation therapy, have limitations in terms of efficacy, side effects, and patient quality of life.
In recent years, cyclodextrins have been explored as potential therapeutic agents for cancer treatment. They have been used as drug delivery systems to improve the pharmacokinetics and pharmacodynamics of chemotherapeutic agents, as well as to reduce their side effects. Additionally, cyclodextrins have shown potential in targeting cancer cells and overcoming drug resistance, which is a significant challenge in cancer therapy.
This systematic review aims to evaluate the effectiveness and safety of cyclodextrins in cancer treatment, considering factors such as overall survival, progression-free survival, quality of life, toxicity profiles, and the occurrence of adverse events in clinical studies. | null |
CRD42021247042 | How is transcarotid access compared with transfemoral access for transcatheter aortic valve replacement with regard to safety and efficacy? | Transcatheter aortic valve replacement (TAVR) has evolved as a major therapeutic modality in the management of patients with severe aortic valve stenosis. The transfemoral approach is considered as the access route of choice as it is associated with superb outcomes. As considerate percentage of patients undergoing TAVR evaluation have peripheral vascular disease that precludes transfemoral approach TAVR, other access routes have been utilized as alternatives. Transcarotid access has emerged as an alternative to suboptimal transfemoral access. However, its safety and efficacy remains to be elucidated. We would like to perform a meta-analysis of studies comparing the procedural and clinical outcomes of the transcarotid (TC) and transfemoral (TF) approaches for TAVR. In the absence of a randomized controlled trial, the best available evidence to elucidate this comparison comes from studies that directly compare patients undergoing TF-TAVR and TC-TAVR. Therefore, we performed a meta-analysis of studies comparing both approaches. | null |
CRD420251003457 | The objectives of this meta-analysis are as follows: | The population inclusion criteria for this meta-analysis are as follows: Age: Studies will include both adult and pediatric populations, with participants aged 18 years and older, and/or studies that specifically focus on younger populations (e.g., adolescents) if applicable. Diagnosis of Periodontal Disease: Only studies involving individuals diagnosed with periodontal disease (gingivitis, periodontitis, or chronic periodontitis) based on clinical parameters such as probing depth, clinical attachment loss, and radiographic findings will be included. Lactoferrin Measurement: Studies must measure lactoferrin levels in biological samples such as gingival crevicular fluid (GCF), saliva, serum, or other relevant biological matrices. Both cross-sectional and longitudinal studies examining lactoferrin as a biomarker of periodontal disease will be included. Clinical Relevance: Only studies that examine the role of lactoferrin in relation to periodontal disease parameters such as inflammation, disease progression, severity, or treatment outcomes will be included. Studies evaluating the potential of lactoferrin as a diagnostic tool or predictor of treatment response will also be considered. Language: Studies published in English will be included. Non-English studies will be excluded unless they have a reliable English abstract or translation. Study Design: Eligible study designs include randomized controlled trials (RCTs), case-control studies, cross-sectional studies, Non randomized interventional study. Lactoferrin; Enzyme-linked immunosorbent assay; Diagnostic Procedure Studies must involve the measurement of lactoferrin levels in biological fluids such as gingival crevicular fluid (GCF), saliva, or serum. Lactoferrin must be evaluated as a potential biomarker to assess periodontal disease or its progression, inflammation, or severity. Lactoferrin measurement techniques should be standardized and reliable (enzyme-linked immunosorbent assay [ELISA]). Exposure to Periodontal Disease: Studies involving individuals diagnosed with periodontal disease (gingivitis, periodontitis, or chronic periodontitis) will be included. This includes both mild and severe cases of periodontal disease, based on clinical parameters such as probing depth, attachment loss, and inflammation. Periodontal disease exposure could be evaluated at different stages and under various conditions Monitoring and Treatment Exposure: Studies examining lactoferrin levels before and after periodontal treatment or intervention (such as scaling and root planing, antibiotic therapy, or surgical procedures) will be included to assess whether lactoferrin can track disease progression or response to treatment. Studies involving systemic treatments that may influence lactoferrin levels as part of periodontal disease management will be included. Longitudinal or Cross-Sectional Exposure: Exposure to Specific Risk Factors: Studies exploring the impact of systemic risk factors on lactoferrin levels in the context of periodontal disease will be included, as these factors can influence both periodontal disease progression and lactoferrin expression. PICO tags selected: Lactoferrin; Enzyme-linked immunosorbent assay; Diagnostic Procedure or this meta-analysis on the role of lactoferrin in periodontal disease, comparator inclusion criteria are as follows: Healthy Control Groups: Studies that include healthy control groups with no periodontal disease will be considered. These groups serve as a baseline to compare lactoferrin levels between individuals with periodontal disease and those without, enabling an assessment of the biomarker's diagnostic ability. Periodontal Disease Severity Groups: Studies that differentiate between varying degrees of periodontal disease severity (e.g., gingivitis, mild, moderate, and severe periodontitis) will be included. Comparisons between lactoferrin levels across different stages of the disease will help determine its relationship with disease progression and severity. Other Biomarkers: Studies that compare lactoferrin levels will also be included. Treatment or Intervention Comparisons: Studies that compare lactoferrin levels before and after periodontal treatment (e.g., scaling and root planing, antibiotic therapy, or surgical interventions) will be included. This will provide insights into how lactoferrin can be used to monitor disease progression or response to treatment. Systemic Health Comparisons: Studies that include individuals with systemic health conditions (such as diabetes or cardiovascular diseases) alongside periodontal disease will be included. The types of studies that will be included in this meta-analysis are as follows: Randomized Controlled Trials (RCTs): Studies that assess the role of lactoferrin as a biomarker in periodontal disease, with random allocation of participants to different interventions or observational groups, will be included. These studies provide high-quality evidence due to their rigorous design. Cohort Studies: Studies that follow groups of individuals with periodontal disease over time, measuring lactoferrin levels and observing disease progression or treatment outcomes, will be included. These studies are valuable for understanding the relationship between lactoferrin and long-term clinical outcomes. Case-Control Studies: Studies that compare lactoferrin levels in individuals with periodontal disease to those without the disease (controls) will be included. These studies are useful for identifying biomarkers associated with the presence of periodontal disease. Cross-Sectional Studies: Studies that measure lactoferrin levels at a single point in time in individuals with varying stages of periodontal disease will be included. These studies provide insights into the correlation between lactoferrin and clinical parameters of disease severity. Observational Studies: Studies that observe and record lactoferrin levels in relation to periodontal disease without intervening in the course of disease treatment or progression will be included. These studies contribute to understanding the natural relationship between lactoferrin and periodontal health. | Non-periodontal Disease Populations: Studies involving individuals without a diagnosis of periodontal disease (e.g., healthy controls or those with other oral conditions not related to periodontal disease, such as dental caries or oral cancer) will be excluded. Non-human Studies: Animal studies, in vitro studies, and studies not conducted on human populations will be excluded from the analysis. Incomplete or Inadequate Lactoferrin Measurement: Studies that do not measure lactoferrin levels in relevant biological samples (such as gingival crevicular fluid, saliva, or serum) or those with unreliable or inconsistent lactoferrin measurement methods will be excluded. Lack of Relevant Clinical Data: Studies that do not include information about clinical parameters of periodontal disease (such as probing depth, clinical attachment loss, or gingival inflammation) or fail to link lactoferrin levels to these parameters will be excluded. Interventions with Lactoferrin: Studies that focus on the therapeutic use of lactoferrin as an intervention for periodontal disease, rather than its role as a biomarker, will be excluded. Language Limitations: Studies published in languages other than English will be excluded unless there is a reliable English translation or abstract. Study Design: Case reports, reviews, editorials, and expert opinions will be excluded . Studies without Standardized Lactoferrin Measurement: Studies that do not measure lactoferrin reliably or use non-standardized methods (e.g., qualitative assessments or unvalidated assays) will be excluded. To ensure the reliability and consistency of results, studies must employ validated quantitative techniques (such as ELISA or immunohistochemistry) to assess lactoferrin levels. Studies Focusing on Non-Human Populations: Studies with Inadequate Data on Lactoferrin Levels: Studies with Irrelevant or Non-Comparable Comparators: Studies that compare lactoferrin levels to biomarkers that are irrelevant to periodontal disease (e.g., biomarkers for unrelated diseases such as cancer, or biomarkers with no known association with periodontal inflammation) will be excluded. Studies with inappropriate comparators (such as comparing lactoferrin to other biomarkers not used in clinical practice for periodontal disease) will be excluded to maintain clinical relevance. Studies Involving Disease other than periodontitis populations: Studies Not Reporting Clinical Outcomes: Studies that do not provide clinical outcomes related to periodontal disease progression or response to treatment (such as changes in clinical attachment loss, probing depth, or gingival inflammation) will be excluded, as the aim is to evaluate the clinical utility of lactoferrin as a biomarker. Studies Published in Non-English Languages. For this meta-analysis on the role of lactoferrin in periodontal disease, comparator exclusion criteria are as follows: Studies Without Relevant Control Groups: Studies that do not include a comparator group, such as healthy controls or individuals without periodontal disease, will be excluded. Without a proper comparator group, it becomes difficult to assess the specificity and diagnostic accuracy of lactoferrin as a biomarker for periodontal disease. Studies with Non-Periodontal Disease Comparators: Studies that compare lactoferrin levels in individuals with periodontal disease to groups with non-oral diseases (such as cancer, autoimmune diseases, or other systemic conditions) but no periodontal involvement will be excluded, as they do not provide relevant comparisons for understanding lactoferrin's role in periodontal disease. Studies with Inappropriate or Unmatched Comparator Groups: Studies where comparator groups are not appropriately matched will be excluded due to the potential for biased or unreliable comparisons. Studies with Inconsistent or Irrelevant Comparator Biomarkers: Studies that compare lactoferrin to biomarkers that are not clinically relevant or routinely used in periodontal disease diagnosis will be excluded. Comparisons to non-specific or irrelevant biomarkers would undermine the focus of the analysis. The types of studies that will be excluded from this meta-analysis are as follows: Case Reports: Single-case studies that report on individual patients will be excluded due to the lack of generalizability and limited statistical power. Review Articles and Meta-Analyses: Studies that provide summaries or analyses of existing literature, without original primary data, will be excluded to avoid duplication and ensure that only original research is considered. Editorials and Expert Opinions: Opinion-based articles or editorials that do not involve original research or empirical data will be excluded, as they do not contribute direct evidence to the role of lactoferrin in periodontal disease. Animal Studies: Studies conducted on animals, including in vivo or in vitro studies, will be excluded since the focus of this meta-analysis is on human populations with periodontal disease. Non-English Studies: Studies published in languages other than English will be excluded unless they have a reliable English abstract or translation available. |
CRD42024547794 | 1. What is the efficacy of the Coronary Sinus Reducer (CSR) in refractory angina?
2. What is the level of improvement in Canadian Coronary Society (CCS) angina class after using CSR? | Refractory angina significantly impairs patients' quality of life and is associated with increased morbidity and mortality. The study evaluates the impact of CSR on improving Canadian Cardiovascular Society (CCS) angina class, a widely used measure of angina severity and symptomatology. By synthesizing data from multiple studies, the analysis aims to provide comprehensive insights into the effectiveness of CSR as a therapeutic option for refractory angina patients, with a particular focus on its ability to alleviate angina symptoms and enhance functional capacity.The existing literature is inadequate in refractory angina patients given CSR. | null |
CRD420250640449 | Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent synovitis and progressive joint damage. Radiographic progression remains a key outcome for assessing disease activity and the efficacy of therapeutic interventions. Given the financial and safety considerations associated with long-term treatment, tapering strategies are increasingly being explored. However, the effect of treatment tapering on radiographic progression is not fully understood, necessitating a comprehensive synthesis of available evidence. This systematic review aims to identify, appraise, and synthesize data from randomized controlled trials (RCTs) that evaluate the impact of tapering versus continuation of stable treatment on radiographic outcomes in RA. | We are studying the effects of treatment tapering in rheumatoid arthritis and whether this leads to subclinical progression with increasing erosions (either in size or by number). • Adults (aged ≥18 years) with a diagnosis of RA according to the ACR/EULAR criteria or equivalent.• Participants must be on stable therapy at baseline. • Treatment tapering strategies, including:o Dose reduction (partial taper).o Treatment cessation. • Continuation of stable treatment at the standard dose. | null |
CRD42023453299 | What are the most promising advances and the most recent revolutionary approaches in immunotherapy and gene therapy for cancer treatment? | Cancer is a disease characterized by the uncontrolled growth and spread of abnormal cells in the body. As cancer cells multiply, they can evade the immune system. This pathology continues to be one of the leading causes of mortality globally. Over the decades, advances in medical research have unraveled numerous mechanisms underlying carcinogenesis and have provided therapeutic tools to address this complex disease. Immunotherapy capitalizes on the inherent power of the immune system to recognize and eliminate malignant cells, while gene therapy offers the possibility of correcting, replacing or enhancing specific genes to counteract the genetic basis of carcinogenesis. These approaches, although still under development, have shown promising results in a variety of cancers and have revitalized hopes for a more precise and effective therapeutic strategy. | null |
CRD42022307908 | The aim of this systematic review is to identify and collate evidence from clinical studies that have implemented and/or evaluated Clinical Decision Support Systems (CDSS) for the diagnosis and/or management of people with a diagnosis of both Asthma and COPD. | Use of CDSS for people with a diagnosis of both Asthma and COPD. | null |
CRD420251011058 | To evaluate the efficacy of GLP-1 analogs in the treatment of idiopathic intracranial hypertension, comparing them to | Patients with active idiopathic intracranial hypertension, characterized by intracranial pressure greater than 25 cmH2O (measured by lumbar puncture) and the presence of papilledema. Exenatide; Liraglutide; Semaglutide Inclusion criteria for the intervention: Patients treated with GLP-1 analogs (such as exenatide, liraglutide, semaglutide, dulaglutide, or tirzepatide) for the management of idiopathic intracranial hypertension. The intervention may be administered at various dosages and frequencies according to the available therapeutic protocols. PICO tags selected: Placebo; Attention Placebo Control Patients who received placebo as treatment for idiopathic intracranial hypertension. Therapeutics, Randomized Clinical Trials and Observational studies | null |
CRD42025631708 | Hesperidin has been shown to provide significant benefits for conditions such as diabetes and hypertension, supported by both preclinical and clinical evidence. In this systematic review and meta-analysis, we aim to explore the therapeutic effects of hesperidin in treating metabolic syndrome based on available randomized controlled trials.We will consider parameters such as blood pressure, glycemic index parameters (fasting blood glucose, HbA1c,) BMI, Lipid profile, lipoprotein (a), hsCRP etc. | Metabolic syndrome, including its associated components such as obesity, Blood Pressure, dyslipidemia, Cardiovascular Disease, hypertension, and inflammation, with a focus on evaluating the therapeutic effects of hesperidin." | null |
CRD42024528497 | We propose a review to provide a systematic compendium of the effectiveness of piano music therapy in the recovery of upper limb movement function post-stroke. Around the world, stroke is an important public health challenge. Upper limb motor dysfunction is a common complication of post-stroke , affecting patients' daily activities and emotional state, and placing a heavy burden on patients and their families. Previous research indicates that piano music therapy can enhance patients' fine motor control by guiding them to exercise their dysfunctional limbs over time, increasing neuroplasticity . In addition, the pleasurable experience and emotional relief effects of piano performance can also help to improve patients' psychological state. Despite preliminary evidences supporting the potential of piano music therapy in stroke rehabilitation, its efficacy and sustainability still need to be more rigorously reviewed and validated . In this paper, we will conduct a review to systematically collate the clinical evidence under different variable conditions, to provide mainstream scientific evidences and guidance of credible value for the rehabilitation treatment of stroke patients, and to promote the application and development of this treatment in the field of rehabilitation. | Stroke is the second leading cause of death in the world, with a correspondingly extremely high risk of disability. However, we have to be aware of the fact that the incidence of stroke in young and middle-aged people is still increasing significantly around the globe, predicted the trend of stroke mortality between 2020 and 2050, stating that in the next three decades the stroke mortality rate will increase by 50 percent on the basis of the current data. Meanwhile, the disability index after stroke will grow from 144.8 million visits in 2020 to 189 million in 2050. Movement disorders and restricted mobility are among the most common problems after stroke. It has been shown that at least half of patients within the 6-month post-stroke period and in the patient population over the age of 65 years experience persistent hemiparesis, with 80%-95% of stroke survivors having concomitant upper limb motor dysfunction. This problem not only causes difficulties in daily living, but also affects emotional well-being and life quality. Therefore, participation in a rehabilitation programme aimed at promoting adaptive motor learning is essential for the recovery of motor function and self-care in stroke patients. | null |
CRD42023444305 | i. What is the number of evidence-based interventions or strategies from clinical and allied health research that has been successfully adopted and integrated into practice (T3) in Malaysia?
ii. What are the unique characteristics of clinical and allied health research that have been translated into practice compared to those that did not in Malaysia? | The translation research continuum (T models) with 5 phases of translational research (T0 to T4) is commonly used to describe the translation process from basic research to the community. T0 is basic science research including preclinical and animal studies, which define mechanisms, targets, and lead molecules. T1 is defined as a translation to humans that moves basic discovery through early-phase clinical trials (Phase 1 clinical trials) to human health applications such as new methods of diagnosis, treatment, and prevention. T2 is denoted as the translation to patients that includes Phase 2 and 3 clinical trials and controlled studies leading to clinical application and the development of evidence‑based guidelines. T3 deals with the translation to practice that includes Phase 4 clinical trials, comparative effectiveness research, post‑marketing studies, clinical outcomes research, health services, dissemination, and implementation research which attempts to move evidence-based guidelines into health practice. T4 incorporates the translation to the community that includes population-level outcomes research, monitoring of mobility, mortality, benefits, risks, impacts of policy, and change with the aim to benefit society. | null |
CRD42023337830 | Does Catalpol have neuroprotective effect in animal models of acute focal ischemic stroke and what are the possible mechanisms involved ? | Ischemic stroke Acute permanent Middle cerebral artery occlusion (MCAO) or temporary Middle cerebral artery occlusion (MCAO) animal models (all species, all sexes) All timings, frequencies and dosages of treatment with catalpol are eligible for inclusion. Purified water-treated, vehicle-treated, saline-treated and sham-treated control animals
No treatment control animals | animals with co-morbidities,
ex-vivo, in-vitro and in-silico models
not a focal cerebral ischemic stroke model, such as traumatic, global, chronic cerebral ischemia models Catalpol not used as monotherapy Other Chinese herbal medicine or Western medicine |
CRD42023389658 | The aim of this systematic review is to investigate if there are any associations between comorbidities and disease outcomes in the multiple sclerosis population, as measured using, a) clinical measures such as disability, b) disease course such as clinical relapses, and/or c) MRI-related metrics.
Comorbidity is a co-existing condition not directly related to the primary disease, in our case, multiple sclerosis (MS). In this review, we focus on overall burden (number of comorbidities) and specific comorbidities such as depression, anxiety, hypertension, hyperlipidemia, and chronic lung diseases. | Multiple sclerosis: Multiple sclerosis (MS) is an immune-mediated, chronic inflammatory, and degenerative disease of the central nervous system, resulting in a range of neurological symptoms. In 2020, there were an estimated 2.8 million people worldwide affected by MS.
Recently, many studies noted that comorbidities in persons with MS are associated with diagnostic delays, and increased disability progression and disease activity. Modifying or managing comorbidity burden could be as important a factor as use of disease-modifying therapies on the health outcomes in persons with MS. Thus, in this systematic review, we will be focusing on whether there are any associations between comorbidities (overall burden or any specific comorbidity, such as depression, anxiety, hypertension, hyperlipidemia, or chronic lung disease) and outcomes of MS: 1) relapse rate, 2) disability, 3) brain lesions on MRI. | null |
CRD420251010037 | To systematically review and meta-analyze randomized controlled trials (RCTs) evaluating the effectiveness of LWJXD combined with ZSP for chronic cough. | 1. Diagnosis of Chronic Cough: Patients must be diagnosed with chronic cough, which is typically defined as a cough lasting for more than 8 weeks. This diagnosis should be confirmed by a qualified medical professional based on clinical symptoms and, if necessary, additional diagnostic tests. 2. Treatment with Linggan Wuwei Jiangxin Decoction Combined with Zhisou San: Patients must have undergone treatment with Linggan Wuwei Jiangxin Decoction combined with Zhisou San, either as the primary or adjunctive therapy for their chronic cough. LWJXD combined with ZSP, administered orally. Any other pharmacological or non-pharmacological intervention, placebo, or usual care. | 1. Alternative Diagnoses: Patients with alternative diagnoses that could explain their chronic cough, such as chronic obstructive pulmonary disease (COPD), tuberculosis and bronchiectasis, or other respiratory conditions, will be excluded. 2.Patients with a combination of severe heart, brain, kidney and liver diseases and mental disorders. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.